document incorporate reference portion proxy statement file march iiiexplanatory note company restate consolidated balance sheet december consolidate statement earning cash flow comprehensive income retain earning year end december restatement restatement affect period prior impact restatement prior period reflect adjustment opening retain earning january restatement report annual report year end december report amendment quarterly report form q quarterly period end march june september restatement correct certain company historical accounting policy conform generally accept accounting principle gaap ii correct certain error application gaap include revision inappropriate accounting respect company account tax contingency reserve restatement include adjustment earning continue operation minority interest income taxis ii minority interest net taxis iii provision income taxis iv earning discontinue operation v cash cash equivalent restatement adjustment increase company net earning dilute earning share year end december approximately million share reduce net earning dilute earning share year end december approximately million share restatement adjustment company consolidated balance sheet decrease cash cash equivalent december approximately billion increase marketable security consolidate balance sheet december restate cash cash equivalent decrease approximately billion marketable security increase restatement adjustment statement cash flow increase net cash investing activity year end december approximately billion billion respectively impact period prior discussion individual restatement adjustment item financial statementsnote restatement previously issue financial statement year end december additionally item management discussion analysis financial condition result operation information impact restatement year item select financial datum ii report company amend annual report quarterly report form q period affect restatement end prior march financial statement relate financial information contain report long rely reference amount annual report prior period prior period comparison reflect balance amount restate basis item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger company division subsidiary engage discovery development licensing manufacturing marketing distribution sale pharmaceutical healthcare relate product acquisition divestiture october company acquire dupont pharmaceutical business dupont pharmaceutical ei du pont de nemour company billion cash dupont pharmaceutical primarily domestic pharmaceutical imaging product business focus research development addition november company purchase million share imclone system incorporate imclone share million represent share outstanding prior company commencement public tender offer imclone share equity investment imclone strategic agreement company imclone include arrangement codevelop copromote cancer drug erbitux transaction finance proceed issuance billion commercial paper issuance billion mediumterm note internal cash flow company strategy focus pharmaceutical healthcare business company decide divest clairol zimmer business accordingly operation business reflect discontinued operation accompany consolidated financial statement november company complete sale clairol billion august company spin zimmer holdings inc taxfree distribution bristolmyer squibb website company internet website address wwwbmscom company make available free charge website annual quarterly current report include amendment report soon reasonably practicable company electronically file material furnish material securities exchange commission information relate corporate governance bristolmyer squibb include company corporate governance guideline standard business conduct ethic code ethic senior financial officer information concern company executive committee board director board committee include committee charter transaction bristolmyers squibb security director officer available company website wwwbmscom investorscorporate governance caption waiver material amendment code ethic post promptly company website information relate stockholder service include company dividend reinvestment plan direct deposit dividend available company website wwwbmscom investorsstockholder service caption company incorporate reference certain information part proxy statement annual meeting stockholder sec allow company disclose important information refer manner refer information company proxy statement annual meeting stockholder annual report available company website wwwbmscom investorssec filing caption business segment company reportable segmentspharmaceutical oncology therapeutic network otn nutritional healthcare pharmaceutical segment global pharmaceutical international exclude japan consumer medicine business otn segment provide oncology product supportive care product relate supply officebase oncologist united states nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula business healthcare segment consist convatec medical imaging consumer medicine north america japan businesse additional information segment item financial statementsnote segment information pharmaceutical segment pharmaceutical segment discover develop license manufacture market distribute sell brand pharmaceutical product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession company manufacture products united states puerto rico foreign country pharmaceutical sale account approximately company sale company sale domestic pharmaceutical sale account total pharmaceutical sale total pharmaceutical sale total pharmaceutical sale pharmaceutical sales europe account total pharmaceutical sale total pharmaceutical sale total pharmaceutical sale pharmaceutical sale japan account total pharmaceutical sale year company strategy build pipeline support sustainable growth focus discovery development effort disease area increase sale marketing emphasis specialist high value primary care prescriber invest research development establish biologic business addition discover develop product research development effort company actively pursue product research collaboration strategic alliance pharmaceutical industry additional information strategic alliance research development pharmaceutical segment compete worldwide researchbase drug company small research company generic drug manufacturer company expect lose certain revenue year result expiration market exclusivity protection certain product believe revenue loss offset growth inline product include recently launch product subject regulatory approval introduction latestage pipeline product revenue negatively impact competitive factor include relate pravachol outcome plavix litigation information matter product competition research development item management discussion analysis financial condition result operationsoutlook item financial statementsnote legal proceeding contingency product company pharmaceutical revenue come product follow therapeutic class cardiovascular metabolic oncology infectious disease include human immunodeficiency virusacquire immune deficiency syndrome hivaid affective psychiatric disorder pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity market exclusivity base patent right andor certain regulatory form exclusivity patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product company business focus innovative pharmaceutical product company rely patent right form protection maintain market exclusivity product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition company business generic competition chart show net sale key product pharmaceutical segment year basic exclusivity loss patent right datum exclusivity occur expect occur united states european union eu japan company sell pharmaceutical product country datum provide countrybycountry basis individual country sale significant outside united states eu japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval company assess market exclusivity period product casebycase basis length market exclusivity company product difficult predict certainty complex interaction patent regulatory form exclusivity factor assurance particular product enjoy market exclusivity period time company currently anticipate past past past currently currently currently expect expect expect year year year eu japanese basic basic basic restate restate exclusivity exclusivity exclusivity pharmaceutical product loss lossa loss dollar million pravachol plavix taxol paraplatin avaproavalide sustiva monopril glucovance glucophage xr zeritzerit er coumadin b abilify videxvidex ec tequin glucophage ir serzone reyataz buspar note currently expect year basic exclusivity loss include statutory extension exclusivity earn speculative instance laterexpire patent cover particular form compositions drug method manufacture method drug patent result favorable market position company product product exclusivity date specify predict assure company currently market product jurisdiction indicate reference eu include follow current member state austria belgium denmark finland france germany greece ireland italy luxembourg netherlands portugal spain sweden united kingdom instance date basic exclusivity loss different eu member states instances early late date basic exclusivity loss list eu country basic patent obtain datum protection available b eu basic exclusivity expire bms acquire product summary indication intellectual property position license arrangement thirdparty manufacturing arrangement product united states applicable eu japan pravachol pravastatin sodium cardiovascular product hmg coa reductase inhibitor indicate adjunct diet patient primary hypercholesterolemia lower risk heart attack people clinically evident coronary heart disease elevate cholesterol reduce risk heart attack stroke patient clinically evident coronary heart disease company license patent cover pravastatin sankyo company ltd japan sankyo april term license company market sell pravastatin world exclude japan korea taiwan thailand market sankyo retain exclusive patent right sankyo comarkets pravastatin certain european country composition matter patent schedule expire united states october extend month april law provide exclusivity extension pediatric research eu composition matter patent obtain greece luxembourg portugal expire spain july composition matter patent expire august belgium denmark finland germany ireland netherlands united kingdom austria expiration occur november france sweden expiration occur august march respectively italy expiration occur january company bulk requirement pravastatin supply sankyo arrangement include royalty payment base product sale bms finish product facility plavix clopidogrel bisulfate cardiovascular product platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel codevelope jointly market sanofisynthelabo sanofi worldwide alliance operate framework geographic territory americas australia bmss primary territory europe asia sanofis primary territory territory partnership form manage central expense market research development royalty supply finish product individual country country level agreement copromote partnership form party sell single brand comarket party operate sell brand independently place composition matter patent united states expire include statutory patent term extension patent currently subject litigation company continue believe patent valid infringe alliance partner patentholder sanofi vigorously pursue litigation possible time reasonably assess outcome litigation adverse determination litigation time potential generic competition plavix information litigation item financial statementsnote legal proceeding contingency information potential effect generic competition plavix item management discussion analysis financial condition result operationsoutlook eu regulatory datum exclusivity extend key composition matter patent expire bulk requirement clopidogrel supply partnership sanofi produce bulk clopidogrel facility obtain portion bulk clopidogrel requirement party arrangement include royalty payment base product sale partnership produce finished product sale information company arrangement sanofi strategic alliance item financial statementsnote alliance investments taxol paclitaxel oncology product treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment aid relate kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin paclitaxel develop collaborative research development agreement government agreement company obtain right government taxol data active ingredient taxol paclitaxel patent protection united states eu japan regulatory protection form datum exclusivity datum exclusivity united states expire final marketing approval generic paclitaxel occur january data exclusivity eu expire september data exclusivity taxol japan expire july patent claim approve dose administration schedule expire japan numerous factor impossible predict loss market exclusivity japan actually occur information recently settle litigation involve taxol item financial statementsnote legal proceeding contingency company supply bulk requirement paclitaxel party produce finished good facility paraplatin carboplatin oncology product chemotherapeutic agent treatment ovarian cancer company hold exclusive patent license carboplatin research corporation technology rct university michigan company pay royalty base percentage product sale license company right market paraplatin worldwide patent carboplatin expire united states april company conduct pediatric clinical study examine carboplatin completion study timely submission result food drug administration fda company earn exclusivity extension extend exclusivity period united states october assurance exclusivity carboplatin extend result study eu basic patent cover carboplatin obtain france germany netherlands sweden united kingdom patent expire country france japan basic patent expire company obtain bulk requirement carboplatin party produce finished good facility avaproavalide irbesartanirbesartanhydrochlorothiazide cardiovascular product angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi company alliance sanofi operate framework geographic territory bmss primary territory sanofis primary territory basic composition matter patent united states expire eu data exclusivity eu expire irbesartan manufacture bristolmyers squibb sanofi bulk irbesartan sell territory joint venture fix percentage kilo intellectual property license arrangement sanofi collect royalty base percentage net sale information company arrangement sanofi strategic alliance item financial statementsnote alliance investments sustiva efavirenz virology product antiretroviral drug treatment hivaid right market efavirenz united states united kingdom france germany ireland italy spain acquire dupont pharmaceutical acquisition complete october right relate product license merck co royalty base percentage net sale basic composition matter patent expire united states separate method use patent expire basic composition matter patent united kingdom ireland france germany italy spain expire datum exclusivity eu expire company obtain bulk requirement efavirenz party produce finished good facility monopril fosinopril sodium cardiovascular product secondgeneration angiotensin convert enzyme ace inhibitor oncea day dosing indicate treatment hypertension monopril develop internally basic composition matter patent united states expire june basic composition matter patent expire denmark greece portugal spain october composition matter patent obtain finland rest eu composition matter patent expire countrybycountry basis glucophage ir metformin hydrochlorideglyburide metformin hydrochloride metabolic product oral antidiabetic agent type glucophage xr diabete glucovance metformin develop merck sant sas merck sant term arrangement company market sell metformin united states company purchase bulk metformin price include royalty base percentage net sale datum exclusivity glucophage ir expire march regulatory exclusivity expire glucophage xr october glucovance july company earn pediatric exclusivity extension glucovance extend regulatory exclusivity january company obtain bulk requirement metformin merck sant produce finished product facility zeritzerit er stavudine virology product treatment hivaid company hold exclusive patent license zerit yale university pursuant pay royalty base product sale japan company exclusive license zerit yamasa corporation pursuant pay royalty base net sale japan use patent expire united states june pediatric extension earn exclusivity expect expire december patent series expire eu patent application pende denmark finland japan december coumadin warfarin sodium cardiovascular product oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism warfarin acquire dupont pharmaceutical acquisition complete october market exclusivity expire united states basic patent protection regulatory datum protection expire bms acquire coumadin company obtain bulk requirement warfarin party produce majority finish good facility abilify aripiprazole neuroscience product atypical antipsychotic agent patient schizophrenia abilify introduce united states november companys partner otsuka pharmaceutical co ltd otsuka receive approval supplemental new drug application snda aripiprazole maintain stability patient schizophrenia announce submit snda abilify treatment acute mania patient bipolar disorder fda otsuka hold new drug application nda aripiprazole united states marketing authorization application maa eu united states germany spain france company receive fee approximately net sale rest eu company purchase finish product approximately net sale book sale aripiprazole copromote united states company otsuka bmss rights commercialize aripiprazole united states terminate otsuka sole right commercialize aripiprazole united states company right copromote abilify european country united kingdom france germany spain act exclusive distributor product rest eu marketing approval receive european authority february otsuka receive recommendation marketing approval abilify eu committee proprietary medicinal product expert advisory body european commission marketing authorization grant eu european commission company exclusive licensee product rest world exclude japan certain country information company arrangement otsuka strategic alliance item financial statementsnote alliance investment basic composition matter patent expire extend pende supplemental protection extension grant composition matter patent austria belgium finland greece ireland luxembourg portugal eu member states composition matter patent expire extend pende supplemental protection certificate grant otsuka supply bulk requirement aripiprazole otsuka bristolmyers squibb produce finished product facility videxvidex ec didanosine virology product antiretroviral drug treatment adult pediatric patient hivaid didanosine market company different formulation use oral solution second reduce mass tablet enteric coat capsule formulation videx ec company license government patent series claim method didanosine treat hiv patent series cover approve use aforementioned formulation company license non exclusive october company license use patent nonexclusive company potentially obtain license government seek marketing approval government method use patent expire united states includes earn pediatric extension japan europe government grant use patent austria belgium france germany italy luxembourg netherlands sweden united kingdom patent pende ireland expiration use patent eu occur countrybycountry basis method use patent obtain government denmark finland greece portugal spain videx reduce mass formulation company patent cover reduce mass formulation videx united states eu japan expire company attempt develop reduce mass formulation didanosine infringe patent videx ec enteric coat capsule company pende patent application cover videx ec formulation united states eu japan patents issue expiration company attempt develop enteric coat capsule formulation didanosine infringe pende patent application data exclusivity videx ec expire japanese datum exclusivity videx ec expire march company obtain material necessary bulk manufacture didanosine party produce finished product facility tequin gatifloxacin infectious disease product broadspectrum methoxy fluoroquinolone antibiotic indicate treatment respiratory tract infection adult year old acute bacterial exacerbation chronic bronchitis acute sinusitis communityacquire pneumonia cause indicate susceptible strain grampositive gramnegative bacteria gatifloxacin license kyorin pharmaceuticals co ltd company purchase bulk gatifloxacin inclusive royalty base percentage net sale basic patent expire expect patent eligible statutory patent term extension patent term extension grant compensate patent holder portion patent life lose regulatory approval process gatifloxacin manufacture party serzone nefazodone hydrochloride neuroscience product antidepressant treatment serzone subject pende product liability litigation plaintiff allege company know know certain risk associate product fail adequately warn physician user risks discussion litigation item financial statementsnote legal proceeding contingency nefazodone develop internally basic patent expire united states september serzone long market europe canada australia asia reyataz atazanavir sulfate virology product protease inhibitor treatment hivaids reyataz launch united states july company develop atazanavir worldwide license novartis pay royalty base percentage net sale basic composition matter patent expire united states atazanavir receive marketing approval european authority current eu member states application basic composition matter patent pende issue patent expire japan basic composition matter patent expire buspar buspirone hydrochloride neuroscience product antianxiety agent persistent anxiety accompany depressive symptom information recently settle litigation involve buspar item financial statement note legal proceeding contingency buspirone develop internally anxiolytic use patent expire final marketing approval generic buspirone occur march patent outside united states expire erbitux cetuximab biologics product igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux design bind internalize egfr prevent natural ligand call growth factor bind receptor activate signal tumor erbitux approve fda february treatment combination irinotecan patient egfrexpresse metastatic colorectal cancer fail irinotecanbase regimen monotherapy patient intolerant irinotecan eribtux study early stage colorectal cancer type cancer frequently express egf receptor include lung pancreatic ovarian head neck cancer erbitux market north america bristolmyers squibb distribution copromotion agreement imclone accordance agreement company pay imclone million march milestone payment approval erbitux fda company imclone share distribution right erbitux merck kgaa japan description companys alliance imclone strategic alliance item financial statementsnote alliance investment description company supply agreement imclone manufacture quality assurance composition matter patent specifically claim erbitux erbitux approve monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire information biologic patent intellectual property product exclusivity inventorship use patent challenge scientist weizmann institute claim name coinventor information litigation item financial statementsnote legal proceeding contingency european equivalent use patent oppose addition pharmaceutical product discuss company pharmaceutical segment include company wholly own upsa business europe upsa brand acetaminophen efferalgan market pain relief continent company market aspirine upsa dafalgan fervex europe overseas market strategic alliance company enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party alliance form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance reduce risk research development expense lead revenuegenerate product gross margin alliance product generally low substantially gross margin company product profit alliance product share company alliance partner assurance new alliance form company actively pursue arrangement view alliance important complement discovery development activity companys significant current alliance sanofi plavix avapro otsuka abilify imclone erbitux sankyo pravachol additionally company licensing arrangement rct paraplatin yale zerit government videx novartis reyataz kyorin tequin sanofi company enter codevelopment commercialization agreement subsequently restructure sanofi product avaproavalide irbesartan angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy copromote certain country eu trade aprovel comarkete certain country eu company tradename karvea plavix clopidogrel platelet aggregation inhibitor copromote certain country eu tradename plavix comarkete certain country eu company tradename iscover worldwide alliance operate framework geographic territory america australia europe asia territory partnership form manage central expense market research development royalty supply finish product individual country country level agreement copromote comarket place fourth quarter company sanofi modify commercialization arrangement irbesartan united states form copromotion joint venture company contribute irbesartan intellectual property sanofi agree pay company total million million company act operating partner territory cover america principally united states canada puerto rico latin american countries australia own majority control interest territory company consolidate country partnership result territory record sanofis share result minority interest expense net taxis million million million company record sale territory comarkete country germany italy spain greece million million million sanofi act operating partner territory cover europe asia own majority control interest territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million discussion matter item financial statementsnote alliance investment otsuka company enter worldwide commercialization agreement otsuka codevelop commercialize abilify aripiprazole treatment schizophrenia total milestone payment otsuka december million expense company begin copromote product otsuka united states puerto rico november company right copromote product european country marketing approval receive european authority company record alliance revenue share net sale copromotion country record expense relate product company exclusive right sell abilify number country europe latin america asia countries sale commence company record net sale relate cost sale company record revenue abilify million million discussion matter item financial statementsnote alliance investments imclone november company purchase million share imclone share million represent approximately imclone share outstanding prior company commencement public tender offer imclone share imclone biopharmaceutical company focus develop targeted cancer treatment include growth factor blocker cancer vaccine antiangiogenesis therapeutic equity investment imclone strategic agreement company imclone include arrangement codevelop copromote cancer drug erbitux series payment originally total billion company pay imclone milestone payment million march agreement imclone revise reduce total payment million billion revise agreement company pay imclone million march million march accordance agreement company pay imclone march million milestone payment approval erbitux fda payment capitalize amortize cost product sell remain term agreement agreement imclone receive distribution fee base flat rate product revenue north america company purchase commercial requirement bulk erbitux imclone price equal manufacturing cost plus discussion matter item financial statementsnote alliance investment company enter follow significant alliance product clinical development corgentech october company corgentech inc biotechnology company enter agreement jointly develop commercialize corgentechs ef decoy edifoligide novel treatment prevention vein graft failure follow coronary artery bypass graft peripheral artery bypass graft surgery product currently phase iii clinical trial fda grant fast track status indication company expensed initial payment million october potential additional million clinical regulatory milestone payment time arrangement profit share flamel technology sa august company enter exclusive license agreement flamel technologies sa develop market basulin control release unmodified human insulin develop oncedaily injection patient type type diabetes basulin enter phase ii clinical development agreement company lead assume cost future development manufacturing effort basulin exclusive worldwide right product company pay expense million october potential additional million clinical regulatory milestone payment time royalty payment product sale information alliance relate drug discovery research development oncology therapeutic network segment otn lead specialty distributor oncology drug supportive care product relate supply officebase oncologist united states wholesale market cancer pharmaceutical united states see shift administration chemotherapy exclusively hospital set increase administration chemotherapy physician office outside hospital hospitalbase oncologist typically serve drug wholesaler provide daily delivery large quantity pharmaceutical product include oncology drug relate supply hospital pharmacy hospitalbase oncologist rely hospital pharmacy order receive inventory drug maintain clinical drug information officebase oncologist lack hospital pharmacy relate service support generally face significant administrative burden order stocking pay oncology drug relate supply otns objective address cost containment need reduce administrative burden officebase oncologist attempt serve convenient costeffective single source supply oncology drug relate supply reduce inventory associate carry cost increase productivity oncology office provide reliable customeroriente service otn contract individual healthcare provider certain professional organization negotiate discount term behalf member healthcare provider otn provide range oncology product supply variety manufacturer eliminate need customer interact multiple supplier otns product catalog line item manufacturer characteristic market oncology pharmaceutical small number product account majority otns sale otn sale account company net sale company net sale company net sale dollar volume product ship otn million compare million million sale negatively affect new medicare legislation impact oncologist treatment pattern reimbursement level reduce discussion new medicare legislation government regulation price constraint nutritional segment nutritional segment mead johnson manufacture market distribute sell infant formula nutritional product include entire line enfamil product company commence sale enfamil lipil infant formula united states contain nutrient dha docosahexaenoic acid ara arachidonic acid company obtain nutrients sole provider licensing supply arrangement naturally find breast milk dha ara believe support infant brain eye development company nutritional product generally sell wholesaler retailer promote primarily healthcare professional company promote nutritional product directly consumer worldwide advertising company manufacture products united states seven foreign country nutritional sale account company sale domestic nutritional sale account total nutritional sale total nutritional sale total nutritional sale international nutritional sale account total nutritional sale total nutritional sale total nutritional sale approximately onehalf sale infant formula subject rebate issue woman infant child wic program sale subject wic rebate low margin nonwic sale net sale select product product category nutritional segment follows restate restate dollar million enfamil enfalac nutramigen childrens nutritional december strategy focus infant children nutrition mead johnson agree sell adult nutritional business novartis nutrition corporation business unit novartis ag mead johnson adult nutritional brand involve sale include boost complete oral nutritional beverage isocal isotonic tubefeeding formula ultracal general tubefeeding formula adult nutritional product record sale million term agreement mead johnson sell novartis finish good inventory brand trademark patent intellectual property right mead johnson global adult medical nutrition business million include million contingent product conversion million upfront payment supply agreement mead johnson continue manufacture supply majority sell product transaction close february pretax gain approximately million expect record quarter healthcare segment healthcare segment consist convatec medical imaging consumer medicine north america japan healthcare sale account company sale company sale company sale domestic healthcare sale account total healthcare sale total healthcare sale total healthcare sale international healthcare sale account total healthcare sale total healthcare sale total healthcare sale convatec convatec manufacture distribute sell ostomy modern wound skin care product principal brand convatec include natura surfit esteem aquacel duoderm product market worldwide primarily hospital medical profession medical supplier company mainly rely internal sale force sale distributor world company manufacture products united states united kingdom convatec sale account approximately company sale domestic convatec sale account total convatec sale total convatec sale international convatec sale account total convatec sale total convatec sale company announce january agree acquire acordis speciality fibre acordis privately hold company base united kingdom license patent right supply material convatec wound therapeutic line transaction subject regulatory approval receive transaction complete company expect record inprocess research development charge million medical imaging medical imaging manufacture distribute sell cardiovascular imaging product include radiopharmaceutical ultrasound agent principal brand medical imaging include cardiolite definity product market internal sale force sell worldwide primarily radiopharmacie hospital clinic medical profession small concentrated network radiopharmacie distribution connection company international business medical imaging own certain radiopharmacie outside united states cardiolite cover series patent claim component patent coverage differ somewhat countrybycountry basis united states patent expire december company currently expect year basic exclusivity loss eu patent expire december japan patent expire august company manufacture products united states puerto rico medical imaging purchase dupont pharmaceutical acquisition close october medical imaging sale account company sale company sale company sale domestic medical imaging sale account total medical imaging sale total medical imaging sale total medical imaging sale international medical imaging sale account total medical imaging sale total medical imaging sale total medical imaging sale january company enter new license supply agreement cardinal health nuclear pharmacy service provide cardinal right sell cardiolite license pharmacy location consumer medicine consumer medicine manufacture distribute sell overthecounter health care product principal consumer health care brand include excedrin brand product headache relief bufferin analgesic comtrex cold cough flu keri line moisturizer addition company begin market choicedm line diabetic care product august product generally sell retailer promote primarily consumer united states japan advertising product manufacture united states puerto rico japan consumer medicine sale account company sale north american consumer medicine sale account consumer medicine sale consumer medicine sale consumer medicine sale consumer medicine sale japan account consumer medicine sale consumer medicine sale source availability raw material general bristolmyer squibb purchase raw material open market substantially material obtainable number source loss source supply likely material adverse effect company discussion source manufacture quality assurance discussion particular product manufacture quality assurance company seek design operate manufacturing facility maintain inventory way allow meet expect product demand maintain flexibility reallocate manufacturing capacity improve efficiency respond change supply demand pharmaceutical production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval discussion regulatory impact company manufacturing government regulation price constraint pharmaceutical manufacturing facility require significant ongoing capital investment maintenance comply increase regulatory requirement addition company add product line realign focus company expect close partially close modify exist facility devote substantial resource excess historical level convert facility meet heighten processing standard require sterile newly introduce product particular biologic biologic manufacturing involve complex process traditional pharmaceutical operation company capacity manufacture biologic clinical trial commercial launch capacity manufacture large commercial volume product limited biologic important company product portfolio company continue arrangement thirdparty manufacturer substantial investment facility increase maintain capacity produce biologic commercial scale company rely party manufacture supply active ingredient necessary manufacture certain product include pravachol plavix abilify coumadin paraplatin sustiva taxol tequin videxvidex ec maintain stable supply product company take variety action design ensure adequate safety stock ingredient hold thirdparty supplier bristolmyer squibb company manufacturing operation interrupt additional protection case company take step maintain approve backup source available company rely imclone supply erbitux cetuximab bulk requirement commercial use north america japan imclone currently seek company support fda approval manufacture erbitux imclone manufacturing facility somerville new jersey imclone contract lonza biologics plc lonza act manufacturer cetuximab commercial launch cardinal health inc cardinal provide finish assurance imclone grant regulatory approval manufacture erbitux approval occur supply cetuximab obtain lonza exhausted company expect rely lonza manufacture abatacept leay commercial scale product commercialize abatacept leay investigational biologic compound late stage development company filing fda seek approval lonza manufacture company market sell product assurance regulatory approval product obtain company enter agreement lonza reserve portion lonzas biologic manufacturing capacity company future requirement product regulatory approval obtain term agreement company minimum purchase requirement obligate pay lonza onetime termination fee product obtain regulatory approval additional information abatacept leay research development company thirdparty manufacturer company rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet heighten processing requirement biologic company business performance prospect negatively impact additionally company thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason company experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain company pharmaceutical certain circumstance company enter agreement company agree supply product party addition liability arise company failure supply product agreement arrangement require company invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product company success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part company operation include research development purchasing facility planning manufacturing distribution company maintain qualityassurance procedure relate quality integrity scientific information production process control production process involve rigid specification ingredient equipment facility manufacturing method process packaging material label company perform test stage production process final product assure product meet regulatory requirement company standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system company subsidiary thirdparty supplier intellectual property product exclusivity company own license number patent united states foreign country primarily cover pharmaceutical product company develop brand name trademark product area company consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity market exclusivity expire generic version product approve market substantial rapid decline product sale rate decline vary country therapeutic category discussion generic version product impact product sale generic competition product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example united states eu japan provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy regulatory intellectual property right available certain market incentives research new indication orphan drug medicine useful treat pediatric patient regulatory intellectual property right independent patent right company possess particularly important drug lack broad patent protection regulatory form exclusivity prevent competitor gain regulatory approval basis competitor safety efficacy datum drug drug identical market innovator company assess likely market exclusivity period product casebycase basis possible predict length market exclusivity company product certainty complex interaction patent regulatory form exclusivity inherent uncertainty enforceability certain intellectual property right assurance particular product enjoy market exclusivity period time company currently anticipate company expect continue exclusivity challenge year discussion exclusivity challenge pharmaceutical segment item management discussion analysis financial condition result operationsoutlook addition patent regulatory form exclusivity company hold intellectual property form trademark product excedrin enfamil theragran keri bufferin trademark effect market exclusivity product consider marketing value worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely specific aspect law govern market exclusivity pharmaceutical vary country country follow summarize key exclusivity rule market represent significant company sale united states company seek market innovative pharmaceutical united states file complete set safety efficacy datum fda type application file depend drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company file nda medicine biological product biologic license application file type application file affect regulatory exclusivity right competitor seek launch generic substitute chemical innovative drug united states file abbreviate new drug application anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical know new chemical entity entitle year regulatory data protection anda file fda innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation new indication basis new clinical trial receive year datum protection finally nda designate orphan drug drug gain indication treatment condition occur rarely unite state receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use significant portion patent life lose time take obtain regulatory approval innovator extend patent compensate innovator lose patent term specifically innovator identify patent claim product approve method use depend number factor extend expiration patent limit extension maximum patent extend year second extension cause patent effect year date nda approval company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity sixmonth period extend form exclusivity patent regulatory list fda time study complete submit fda currently generic version biological product approve law fda take step allow generic version biologic law change near future competitor seek approval biological product file safety efficacy datum minimum period regulatory exclusivity provide law innovative drug cover patent hold nda sponsor innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator choose file suit generic manufacturer protect patent ndaliste patent successfully challenge innovator chooses sue filer paragraph iv certification entitle day period market exclusivity generic manufacturer time time anda include paragraph iv certification file respect certain company product company evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right recent development united states increase likelihood generic challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product discussion litigation relate patent challenge generic company item financial statementsnote legal proceeding contingenciesplavix litigation reflection statutory incentive challenge patentssix month semiexclusivity certain situationsa describe second new statutory regulatory provision united states limit ability innovator company prevent generic drug approve launch patent litigation ongoing fda actively consider abbreviate regulatory approval process drug similar generic copy innovative drug result development possible predict length market exclusivity particular company product certainty base solely expiration relevant patent current form regulatory exclusivity information new legislation government regulation price constraint european union eu innovative pharmaceutical entitle year regulatory data protection marketing approval obtain centralized procedure consequently regardless innovative medicine cover patent generic copy rely innovator datum usually approve minimum year approval innovative pharmaceutical gain marketing approval noncentralized mutual recognition procedure period year depend individual eu member state regardless regulatory exclusivity competitor obtain approval identical product basis safety efficacy datum time information regulation pharmaceutical product eu government regulation price constraint patent pharmaceutical product generally enforceable eu contrast united states patent list regulatory authority generic copy approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant united states patent eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis general eu law treat chemically synthesize drug biologically derive drug respect intellectual property market exclusivity japan japan medicines new chemical entity entitle year protection approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum protection patent expirations united states patent japan extended compensate patent term lose regulatory review process general japanese law treat chemically synthesize biologically derive drug respect intellectual property market exclusivity rest world country outside united states eu japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar united states eg canada eu eg switzerland develop country adopt patent law andor regulatory exclusivity law develop nation formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto obligation long process assurance outcome assess likely future market exclusivity company innovative drug develop country company take account formal legal right political factor marketing distribution customer companys pharmaceutical segment convatec medical imaging business company promote product medical journal directly health care provider doctor nurse practitioner physician assistant pharmacist hospital pharmacy benefit manager pbms manage care organization mcos government agency company market directly consumer united states directtoconsumer print radio television advertising addition company sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint company sale marketing organization company explain approve use advantage product medical professional company work gain access health authority pbm mco formulary list recommend approve medicine product reimbursement list demonstrate quality treatment benefit product company work mcos pbms assist disease management patient education tool benefit patient improve medical treatment routine market prescription pharmaceutical limit approve use particular product company continue develop information product provide information response inquirie doctor medical professional drug complete clinical trial require regulatory authority safe effective treat medical problem manufacturer choose undertake additional study include comparative clinical trial competitive product demonstrate additional advantage compound study costly year complete result uncertain balancing consideration make difficult decide undertake additional study successful study major impact approve marketing claim strategy company operation include pharmaceutical sale organization sale organization market distinct group product typically base particular therapeutic area physician group sale organization focus sell new product introduce market physician increasingly target specialist high value primary care physician company prescription pharmaceutical product sell principally wholesaler company sell directly retailer hospital clinic government agency pharmacie sale pharmaceutical wholesaler united states mckesson corporation mckesson cardinal amerisourcebergen corporation amerisourcebergen account approximately respectively company total net sale sale amerisourcebergen mckesson account approximately company total net sale sale cardinal account company total net sale sale amerisourcebergen cardinal mckesson account approximately company total net sale sale wholesaler concentrated pharmaceutical segment apart instance company business segment dependent customer group relate customer april company disclose substantial buildup wholesaler inventory pharmaceutical business develop subsequently undertake plan workdown orderly fashion wholesaler inventory level company take step intend moderate investment buy pharmaceutical wholesaler result sale fluctuation unrelated consumer demand company enter new inventory management agreement imas amerisourcebergen cardinal mckesson wholesaler agreement term year cancelable party year ima generally establish limit inventory level bms pharmaceutical product hold wholesaler permit limited buyin bms pharmaceutical product wholesaler price increase preprice increase price require wholesaler provide company datum association wholesaler sale inventory level bms pharmaceutical product otn act bmss exclusive sale distributor bms oncology product officebase oncologist otn believe extensive customer base couple overall competitive pricing customer service attractive drug manufacturer wish serve officebase oncologist community focus distribution channel otn provide service manufacturer include support product launch customer specific marketing program datum service rapid market research company enter agreement mckesson mckesson act exclusive distributor pharmaceutical product otn term agreement mckesson provide warehousing packing shipping purchase inventory management administrative support service bms product pharmaceutical product market promote sell otn otn recognize revenue term mckesson agreement consignment model describe item financial statementsnote accounting policy revenue recognition company exclusive distributor erbitux north america otn term agreement mckesson mckesson provide otn warehousing packing shipping filling order erbitux maintain integrity product special storage condition handle require accordingly sale erbitux include purchase request wholesaler process otn mckesson ship erbitux enduser product intermediary hold later sale information sale marketing consumer medicine nutritional nutritional segment healthcare segmentconsumer medicine competition market bristolmyer squibb compete generally broadbase highly competitive principal mean competition vary product category business group company pharmaceutical segment compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate cost effectiveness marketing effectiveness product label service research development new product process sale company product impact new study indicate competitor product great efficacy treat disease particular form disease company product company sale impact additional labeling requirement well tolerability safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage companys product subject progressive price reduction decrease volume sale example grow market statin reduce cholesterol pravachol company large product net sale compete establish brand new entrant world large pharmaceutical company product beginning lose exclusivity market loss exclusivity expect rate decline market share accelerate recent clinical study successfully compete business manage care pharmacy benefit management organization company demonstrate product offer medical benefit cost advantage compare form care new product company introduce compete product market product later develop competitor manufacturer generic pharmaceutical typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product certain country outside united states patent protection weak nonexistent company compete generic version shortly launch innovative product company large small manufacture sell product similar market company nutritional healthcare segment source competitive advantage include product quality efficacy brand identity advertising promotion product innovation broad distribution capability customer satisfaction price significant expenditure advertising promotion marketing generally require achieve consumer trade acceptance product company believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment assurance company research development effort result commercially successful product product process outmoded time time result product process develop competitor manage care organization growth mcos united states major factor competitive makeup healthcare marketplace half population participate version manage care size patient population cover mcos marketing prescription drug pbms serve organization important company business mco include medical insurance company medical plan administrator healthmaintenance organization alliance hospital physicians physician organization organization consolidate few large entity enhance purchasing strength importance company major objective mco contain possible reduce health care expenditure typically use formulary volume purchase longterm contract negotiate discount pharmaceutical provider mcos pbms typically develop formulary reduce cost medication formulary base price therapeutic benefit available product generally low cost generic medicine favor breadth product cover formulary vary considerably mco formulary include alternative competitive product treatment particular medical problem mcos use variety mean encourage patient use product list formulary exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price company generally universally successful major product include mco formulary generic competition big competitive challenge company face united states internationally generic pharmaceutical manufacturer expiration loss market exclusivity product company lose major portion sale product short period time united states fda approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy pioneer product generic competitor operate company large research development expense cost convey medical information product medical community information market exclusivity intellectual property product exclusivity rate sale decline product expiration exclusivity vary country general decline market rapid develop country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribe primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture note mco focus primarily immediate cost drug favor generic brandname drug government encourage use generic alternative brandname drugs health care program laws united states generally allow case require pharmacists substitute generic drug rate government procedure therapeutically equivalent brandname drug substitution prescribe physician expressly forbid law policy provide add incentive generic manufacturer seek marketing approval automatic substitution remove need generic manufacturer incur sale marketing cost innovator incur research development company invest heavily research development believe critical longterm competitiveness pharmaceutical research development carry bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development carry facility united states belgium canada france united kingdom management continue emphasize leadership innovation productivity quality strategy success pharmaceutical research institute company spend million million million company sponsor research development activity company sponsor pharmaceutical research development spending include certain payment thirdparty collaboration contract percentage pharmaceutical sale compare end company employ approximately people research development company include pharmaceutical research institute include substantial number physician scientist hold graduate postgraduate degree higher skilled technical personnel company concentrate pharmaceutical research development effort follow disease area affective psychiatric disorder alzheimersdementia atherosclerosisthrombosis diabete hepatitis hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant company continue analyze selectively pursue promising lead therapeutic area addition discover develop new chemical compound company look way expand value exist product new use formulation provide additional benefit patient supplement company internal effort company collaborate independent research organization include educational institution researchbase pharmaceutical biotechnology company company contract performance research facility company use service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product company actively seek investment external research technology hold promise complement strengthen research effort investment form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint ventures drug development timeconsume expensive risky development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug market united states record datum preclinical clinical experience include nda biological product license application bpla fda require approval development certain product subject government regulation cover safety efficacy united states foreign country assurance compound result particular program obtain regulatory approval necessary market particular disease indication average thousand chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine process discovery regulatory approval typically take year long drug candidate fail stage process latestage product candidate fail receive regulatory approval company believe investment research internally collaboration reward number new pharmaceutical compound indication stage development bristolmyers squibb drug discovery program include alliance collaborative agreement agreement bring new product pipeline help company remain cut edge technology search novel medicine example december company form partnership lexicon genetic incorporate lexicon develop drug field depression anxiety schizophrenia pain alzheimer disease term agreement lexicon contribute product drug discovery programs alliance company exclusive access discovery neurological sciences field lexicon gene analysis program know genome lexicon receive upfront payment million bristolmyer squibb fourth quarter expense company receive minimum million research funding year agreement bristolmyer squibb option extend agreement year return provide additional research funding million lexicon receive fund novel drug develop alliance earn royalty sale drug commercialize bristolmyers squibb december company announce extension expansion oncology research collaboration exelixis inc exelixis company continue identify validate molecular target implicate genesis cancer original agreement establish threeyear term july term extend collaboration bms provide exelixis upfront payment million increase annual research funding milestone payment certain cancer target arise collaboration exelixis bristolmyer squibb agree extend collaboration december bristolmyers squibb right continue collaboration july goal extension increase total number degree validation cancer target exelixis deliver company exelixis bristolmyer squibb maintain option obtain exclusive worldwide right equal number validate target arise collaboration list investigational compound company later stage development compound enter phase iib phase iii clinical trial investigational compound ultimately company market product depend result preclinical clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale company expect file fda approval abatacept entecavir muraglitazar early note assurance company seek regulatory approval compound approval sought obtain stage development company determine intellectual property issue patent protection available investigational compound patent coverage highlight include potential term extension abatacept ctlaig biological product develop internally currently phase iii clinical trial fusion protein novel immunosuppressive activity target initially rheumatoid arthritis company series patent cover ctlaig method use late composition matter patent expire united states repligen corporation repligen patent claim use ctlaig treat specific autoimmune disease include rheumatoid arthritis litigation concern inventorship ctlaig ongoing information litigation item financial statementsnote legal proceeding contingency entecavir entecavir develop internally currently phase iii clinical trial potent selective inhibitor hepatitis b virus company composition matter patent expire united states ef decoy edifoligide develop jointly corgentech enter phase iii clinical trial novel treatment prevention vein graft failure follow coronary artery bypass graft peripheral artery bypass graft surgery company license corgentechs numerous issue pende patent application cover product patent issue united states expire ixabepilone ixabepilone epothilone develop internally currently phase iii clinical trial novel tubulin inhibitor multiple tumor type company composition matter patent united states expire muraglitazar muraglitazar develop internally currently phase iii clinical trial dual ppar agonist treatment type diabete metabolic disorder company compositionofmatter patent expire united states leay leay biological product develop internally currently phase iib clinical trial fusion protein novel immunosuppressive activity target solid organ transplant company pende patent application united states eu japan cover leay razaxaban razaxaban currently phase iib clinical trial factor xa inhibitor prevention deep vein thrombosis razaxaban acquire company acquisition dupont pharmaceutical develop internally company composition matter patent expire united states company competitor devote substantial fund resource research development addition consolidation occur company industry create company substantial research development resource extent company competitor successful research result erosion sale product unanticipate product obsolescence government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion company product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition company operation subject complex federal state local foreign environmental occupational safety law regulation company anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda united states jurisdiction virtually company business impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance company pharmaceutical product fda regulate company nutritional healthcare product case fda requirement increase time money necessary develop new product bring market united states company pharmaceutical product subject premarket approval requirement united sates new drug approve subject fdc act relate regulation biological drug subject fdc act public health service act know phs act relate regulation biological drug license phs act fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production record keep quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy product occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market company materially adversely affect business financial condition result operation marketing authorization company product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act know pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel record keep packaging quantity label product handle facility storage security requirement intend prevent sale pharmaceutical product sample diversion company subject jurisdiction federal state regulatory enforcement department agency federal trade commission ftc department justice department health human services united states company license drug enforcement agency procure produce control substance company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy federal state agency regulatory authority manufacture storage transportation disposal medical imaging product radioactive nature company activity outside united states subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country eu way company obtain marketing authorization pharmaceutical product route centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product product receive approval centralized procedure automatically receive approval member state eu company obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure month year obtain second route obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state set forth pricing reimbursement product continue subject member state law fda approval approval european medicine evaluation agency obtain product approval product comparable regulatory authority country outside united states eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require united states approval country assure product approve country market outside united states company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact theboard price cut method cost control exception germany united kingdom european country market price new medicine pricing freedom limited united kingdom operation profit control scheme germany operation reference price system company face significant delay market access new product year elapse new medicine available national market additionally member states eu regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential europe different national pricing reimbursement law lead significant parallel trade flow recent year congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose similar issue exist foreign country company business december new medicare legislation enact provide outpatient prescription drug coverage senior citizen united states legislation interim drug discount card program schedule begin june main drug benefit eligibility standalone drug plan schedule begin new drug benefit administer regionally private insurance plan pharmacy benefit manager law allow medicare negotiate directly pharmaceutical company region private drug benefit program legislation allow importation expensive prescription drug canada health human service department certifie safety far assurance certification requirement maintain future legislation certification continue withhold company predict potential impact legislation business clear law implement regulator receive consumer physician impact negative company oncology business reimbursement level reduce certain oncology product administer outpatient setting include paraplatin impact negative intermediate long term company pharmaceutical business generally great federal involvement budget constraint increase likelihood pricing pressure control future federal state government pursue direct method reduce cost drug pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense united states governmental costcontainment effort extend federally fund special supplemental nutrition program wic state participate wic sought obtain rebate manufacturer infant formula product program state conduct competitive bidding infant formula contract require use specific infant formula product state wic program physician request noncontract formula wic customer state participate wic require engage competitive bidding use cost containment measure yield saving equal great saving generate competitive bidding system mead johnson participate program approximately sale subject rebate wic pende pharmaceutical legislation eu expect adopt year impact procedure authorization pharmaceutical product eu centralize mutual recognition procedure particular legislation contain new data protection provision product regardless approve centralized nationalmutual recognition procedure subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority generic company commercialize product year elapse initial marketing authorization grant innovator possible year extension available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment transitional provision new datum protection requirement expect provision apply new innovator product approve new legislation japan recently adopt regulation file new drug effective july streamline filing process international company introduce new compound japan allow international clinical nonclinical datum filing process plan merger japanese pharmaceutical regulatory office lead gain efficiency timeliness drug registration japan price policy pharmaceutical japan remain challenge biannual government mandate price reduction environmental regulation company facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require company operation permit subject modification renewal revocation issue authority corporate environment health safety group monitor operation world provide company overview regulatory requirement oversee implementation company standard compliance company incur operate capital cost matter ongoing basis company expend approximately million million capital environmental project undertake specifically meet environmental requirement respectively expect spend approximately million company believe substantial compliance applicable environmental health safety requirement permit require operation company incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law company current facility operation year time company operator facility generate store dispose substance waste consider hazardous environmental law result soil groundwater certain facility contaminated company require significant expenditure investigate control remediate contamination company potentially responsible environmental condition number waste disposal reprocess facility operate party currently company involve investigation remediation activity approximately site name potentially responsible party prp comprehensive environmental response compensation liability act cercla approximately site cercla similar state statute impose liability entire cost investigation remediation contaminate site party regardless fault ownership time disposal release generally multiple potentially responsible party liability apportion base nature hazardous substance dispose party site number financially viable party base company current estimate cleanup cost expect share financial responsibility company expect expenditure connection cercla remediation matter material expenditure rise future substantial unknown contamination discover company current facility prps fail participate costshare site financial responsibility additional information matter item financial statementsnote legal proceeding contingency employee bristolmyer squibb employ approximately people december foreign operation company significant operation outside united states conduct company subsidiary distributor involve business segmentspharmaceutical nutritional healthcarea companys operation revenue operation outside united states billion account company total revenue revenue exceed million country outside united states single country outside united states contribute company total revenue geographic breakdown net sale yearend asset table caption geographic item financial statementsnote segment information international operation subject certain risk inherent conduct business abroad include currency fluctuation possible nationalization expropriation price exchange control limitation foreign participation local enterprise restrictive governmental action company international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase reduce report dollar value company net asset result operation change foreign exchange rate net favorable impact revenue company predict certainty future change foreign exchange rate effect company attempt mitigate impact operational mean financial instrument discussion item financial statementsnote financial instrument december approximately billion cash cash equivalent marketable security hold company foreign subsidiary company expect repatriate foreseeable future company expect cash generate operation borrowing capital market sufficiently cover cash need work capital capital expenditure dividend repatriation cash united states require additional tax provision reflect consolidated financial statement discussion matter item management discussion analysis financial condition result operationscritical accounting policiesincome taxis item property bristolmyer squibb world headquarters locate park avenue new york new york lease approximately square foot floor space approximately square foot sublet bristolmyer squibb manufacture product major worldwide location aggregate floor space approximately square foot facility own bristolmyer squibb follow table illustrate geographic location company significant manufacturing facility business segment total company pharmaceutical nutritional healthcare united states europe middle east africa western hemisphere pacific total portion facility facility own lease bristolmyers squibb united states research administration storage distribution information company facility item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item submission matter vote security holder matter submit vote security holder fourth quarter year end december ia executive officer registrant list information executive officer company march executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti vice president general manager italy oncology europe division senior vice president president company international senior vice president general manager italy ceei european oncology member executive committee division company president europe present senior vice president president international harrison bain jr vice president treasurer corporate staff company vice president tax treasury vice president act chief financial officer corporate staff company corporate staff present vice president tax treasury corporate staff company stephen e bear vice president strategic business development worldwide beauty carenutritional senior vice president human resource medical device corporate staff company corporate staff vice president marketing business development new york botanical member executive committee gardens nonprofit organization present senior vice president human resource corporate staff company andrew g bodnar md vice president strategic business development worldwide medicine group senior vice president strategy division company medical external affair corporate staff vice president corporate development worldwide medicine group division member executive committee company vice president medical external affair corporate staff company senior vice president medical external affair corporate staff company present senior vice president strategy medical external affair corporate staff company andrew r j bonfield deputy finance director smithkline beecham plc senior vice president chief chief financial officer smithkline beecham plc financial officer corporate staff executive director finance bg group plc member executive committee present senior vice president chief financial officer corporate staff company wendy l dixon phd vice president marketing merck co chief marketing officer president senior vice president merck co global marketing present chief marketing officer president global marketing worldwide medicine member executive committee pharmaceutical group division company current position age employment history past year peter r dolan senior vice president strategy organizational effectiveness corporate staff chairman board chief company executive officer president director company member executive committee present chairman board chief executive officer company donald j hayden senior vice president president worldwide medicine group division executive vice president president company americas executive vice president ebusiness strategy corporate staff company member executive committee executive vice president ebusiness strategy investor relation corporate intelligence corporate staff company executive vice president health care group executive vice president president north america medicines present executive vice president president americas anthony c hooper vice president general manager northern europe international medicine president pharmaceuticals president asiapacific middle east southern africa international medicine member executive committee president intercontinental international medicine president europe africa worldwide medicine group present president pharmaceuticals worldwide medicine group tamar howson senior vice president director business development smithkline beecham senior vice president corporate corporation development corporate staff biotechnology consultant chief executive officer business executive member executive committee present senior vice president corporate development corporate staff company paul w karr deputy controller ge capital services vice president financial controller senior vice president chief accounting officer ge capital markets service corporate staff present vice president financial controller corporate staff company sandra leung associate counsel corporate staff company vice president corporate counsel corporate staff company secretary corporate staff corporate secretary corporate staff company present vice president corporate secretary corporate staff company current position age employment history past year john l mcgoldrick general counsel senior vice president corporate staff company executive vice president general president medical devices group division company counsel corporate staff executive vice president general counsel corporate staff company member executive committee president medical devices group division company present executive vice president general counsel corporate staff company james b palmer md frcp senior vice president director group medical regulatory product strategy chief scientific officer corporate staff glaxo wellcome research development president pharmaceutical research senior vice president new product development glaxosmith kline institute present chief scientific officer corporate staff company president member executive committee pharmaceutical research institute division company elliott sigal md phd vice president apply genomics pharmaceutical research institute division senior vice president global clinical company pharmaceutical development senior vice president early discovery apply technology pharmaceutical pharmaceutical research institute research institute division company member executive committee senior vice president drug discovery exploratory development pharmaceutical research institute division company present senior vice president global clinical pharmaceutical development pharmaceutical research institute division company john l skule presentsenior vice president corporate environmental affair corporate staff senior vice president corporate company environmental affairs corporate staff member executive committee ii item market registrant common stock relate stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange pacific exchange inc symbol bmy bmypr quarterly summary high low market price present common high low high low quarter second quarter quarter fourth quarter prefer high low high low quarter second quarter quarter fourth quarter second quarter quarter trade companys prefer stock prefer stock pay quarterly dividend share holder common stock number record holder common stock december number record holder base actual number holder register book bristolmyers squibb date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company vote security principal holder reference proxy statement file march respect vote security principal holder incorporate reference hereof response information require item dividend dividend declare share common prefer quarter second quarter quarter fourth quarter december board director company declare quarterly dividend share common stock company pay february shareholders record january item select financial datum fiveyear financial summary set forth item revise reflect restatement discussion restatement item financial statement note restatement previously issue financial statement year end december fiveyear financial summary restate restate restate restate million share datum income statement datum net sale earning continue operation minority interest income taxis earning continue operation earning continue operation common share basic diluted average common share outstanding basic dilute dividend pay common prefer stock dividend declare common share financial position datum december total asset cash cash equivalent marketable security longterm debt stockholder equity company record item affect comparability result set forth table item management discussion analysis financial condition result operationsearning year discussion item item management discussion analysis financial condition result operationsnet sale item financial statementsnote alliance investment note restructure item note acquisition divestiture note discontinued operation restatement adjustment affect year set forth follow table include discontinue operation year previously previously report restate report restate dollar million net sale earning continue operation earning continue operation common share basic diluted financial position datum december total asset stockholder equity restatement adjustment affect year adjustment respect net sale intercompany foreign exchange gain loss international pension employee benefit plan accrual income taxis restatement item describe item financial statementsnote restatement previously issue financial statement item management discussion analysis financial condition result operation management discussion analysis financial condition result operation set forth item revise reflect restatement summary company report annual global sale billion sale increase prior year level reflect volume increase net price increase impact foreign exchange fluctuation sale increase partly impact sale workdown non consignment wholesaler inventory international sale increase include favorable foreign exchange impact company product line sale billion eachpravachol plavix pravachol sale grow include favorable foreign exchange impact billion plavix sale grow include favorable foreign exchange impact billion addition product company product line million annual sale include product line million annual sale annual sale excess million earning continue operation minority interest income taxis increase million million net earning continue operation million share basic diluted basis respectively compare million share basic diluted basis company expect exclusivity loss new product mix challenge margin company remain committed invest business maximize key growth driver advance pipeline item affect comparability result discuss earning outlook december company hold billion cash cash equivalent marketable security approximately billion cash cash equivalent marketable security hold company foreign subsidiary company expect repatriate foreseeable future company expect cash generate operation borrowing capital market sufficiently cover cash need work capital capital expenditure dividend repatriation united states require additional tax provision reflect consolidated financial statement discussion matter critical accounting policiesincome taxis company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity additional discussion matter item financial statementsnote legal proceeding contingency longterm debt increase billion december billion december primarily billion fix rate note billion float rate convertible debenture issue august october respectively proceed issuance repay short term borrowing fund cash need operation cash provide operating activity billion work capital billion december company pay dividend approximately billion provide dividend yield consistent company mission extend enhance human life develop highestquality product company invest billion research development growth research development dedicated pharmaceutical product include milestone payment license development program billion percentage pharmaceutical sale compare compound annualize growth pharmaceutical research development spending past year restatement previously issue financial statement company restate consolidated balance sheet december consolidate statement earning cash flow comprehensive income retain earning year end december financial statement second quarter include comparable interim period restatement restatement affect period prior impact restatement prior period reflect adjustment opening retain earning january restatement report annual report year end december report amendment quarterly report form q quarterly period end march june september restatement correct certain company historical accounting policy conform generally accept accounting principle gaap ii correct certain error application gaap late october company determine certain sale certain wholesaler pharmaceuticals business account consignment sale accounting model accordingly determine restate sale earning sale wholesaler follow determination company determine correct certain historical accounting policy conform accounting gaap certain know error application gaap previously record case company believe error material company consolidate financial statement addition restatement process company investigate accounting practice certain area involve significant judgment determine restate additional item respect company conclude error application gaap include certain revision inappropriate accounting march company complete restatement financial statement item restate financial statement year end december include correspond interim period second quarter include comparable prior interim period restatement complete restatement company continue identify implement action improve effectiveness disclosure control procedure internal control financial reporting connection effort company substantially strengthen organization personnel senior financial control function ii adopt rigorous policy procedure respect balance sheet review process iii focus internal audit function financial reporting control iv engage consultant assist evaluation documentation certain financial reporting disclosure process company v engage consultant assist comprehensive detailed review certain company tax reporting accounting addition request company audit committee company independent auditor perform extensive procedure respect company interim financial information base auditor assessment company risk profile expand scope field work perform certain area connection audit company action contribute significantly company identify additional error relate prior period reflect restatement discussion individual restatement adjustment item financial statementsnote restatement previously issue financial statement year end december connection audits restatement company consolidate financial statement year end december company independent auditor pricewaterhousecooper llp pwc identify communicate company audit committee material weakness define standard establish american institute certify public accountant relate company account public financial report significant matter initial recording management review oversight certain accounting matter addition time pwc identify communicate company audit committee reportable condition define standard establish american institute certify public accountant relate company internal control financial reporting income taxis company dedicate substantial resource improve control account financial disclosure reporting auditor identify material weakness connection audit financial statement addition company devote substantial resource remedy reportable condition relation taxis company retain consultant assist comprehensive detailed review certain aspect tax accounting reporting company examine financial reporting taxis significant jurisdiction company subsidiary subject tax result review number prior period error identify reflect restatement addition company undertake review evaluate certain issue raise concern manner company determine provision income taxis company determine prior certain inappropriate adjustment tax contingency reserve improper purpose recording provision income taxis consistent company project effective tax rate addition inappropriate adjustment company complete review able determine error relate tax contingency reserve correct restatement relate inappropriate accounting connection audit company consolidate financial statement year end december pwc advise company audit committee reportable condition income tax accounting area remain company expect complete remediation reportable condition end management discussion analysis financial condition result operation reference amount prior period prior period comparison reflect balance amount restate basis net sale sale billion increase prior year increase sale drive volume increase level partly impact sale workdown nonconsignment wholesaler inventory sale increase million compare decrease million international sale increase million include favorable foreign exchange impact compare increase million significant foreign exchange impact general company business seasonal information pharmaceutical prescriber demand reference table business segment pharmaceutical section set forth comparison change net sale estimate total prescription growth retail mail order customer certain company primary care pharmaceutical product sale billion compare billion increase sale include approximately million million respectively sale relate product acquire dupont pharmaceutical acquisition dupont pharmaceutical complete october domestic sale decrease million international sale increase million foreign exchange significant impact composition net increase sale follows restate volume sell price net foreign exchange increase sale significant portion company pharmaceutical sale wholesaler company experience substantial buildup wholesaler inventory pharmaceutical business year primarily buildup primarily sale incentive offer company wholesaler include discount buyin anticipation price increase extend payment term certain pharmaceuticals wholesaler generally offer end quarter incentive wholesaler purchase product sufficient meet company quarterly sale projection establish company senior management timing company recognition revenue sale wholesaler differ wholesaler period historically company recognize revenue sale shipment product customer gaap revenue recognize substantially risk reward ownership transfer case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment situation describe utilize consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net discount rebate estimate sale allowance accrual return consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis additional discussion company revenue recognition policy item financial statement note accounting policy restatement company restate previously issue financial statement period second quarter correct time revenue recognition certain previously recognize pharmaceutical sale cardinal health inc cardinal mckesson corporation mckesson large wholesaler company pharmaceutical business base application criterion record error time shipment account consignment model december company aggregate cost pharmaceutical product hold cardinal mckesson account consignment model accordingly reflect consignment inventory company consolidate balance sheet approximately million million respectively approximately million million december respectively relate oncology product sell oncology therapeutic network otn defer revenue record gross invoice sale price relate inventory pharmaceutical product account consignment model approximately million million december respectively approximately million million december respectively relate otn result restatement application consignment model approximately million sale exclude otn net discount rebate adjustment reverse period approximately million million recognize respectively consign inventory hold cardinal mckesson work significant portion workdown recognize quarter correspond effect earning continue operation minority interest income taxis increase million million respectively sale cardinal mckesson represent approximately pharmaceutical net sale respectively company estimate base datum note inventory pharmaceutical product hold pharmaceuticals wholesaler range approximately million excess approximately month supply december estimate subject inherent limitation estimate rely thirdparty datum certain thirdparty information form estimate reflect limitation company expect account certain pharmaceutical sale relate otn consignment model agreement mckesson expire earning earning continue operation minority interest income taxis increase million million increase primarily result sale increase specify charge million record litigation settlement asset impairment writeoff process research development increase partially offset increase investment advertising promotion marketing sell administrative expense earning continue operation increase million million basic diluted earning share continue operation increase respectively respectively earning continue operation minority interest income taxis increase million million earning continue operation increase million million basic diluted earning share continue operation increase respectively respectively net earning margin continue operation increase year end december company record item affect comparability result period present set forth follow table discussion item item financial statementsnote alliance investment note restructure item note acquisition divestiture note discontinued operation restate restate dollar million acquire inprocess research development litigation charge net asset impairment charge investment imclone restructuring item gain sale businessesproduct line income tax benefit item settlement prior year tax matter restructure item consist follow cost provision product restructuring year end december sell rd total dollar millions upfront payment licensing agreement accelerate depreciation asset termination benefit exit cost relocation expense asset impairment charge retention benefit change estimate cost provision product restructuring year end december sell rd total dollar million termination benefit exit cost accelerate depreciation asset asset writedown impairment charge change estimate decrease cost provision net product restructuring year end december sale sell total dollar million downsize rationalized operation facility abandonment nonstrategic pharmaceutical product line change estimate gross margin percentage respectively gross margin negatively impact increase sale lowermargin product otn segment million accelerate depreciation charges million charge asset impairment restructuring expense largely offset increase sale high margin product pravachol low gross margin compare principally impact generic competition united states glucophage ir taxol buspar adverse change product mix increase sale otn segment effective income tax rate earning continue operation minority interest income taxis compared increase effective tax rate effective tax rate primarily decrease effective tax rate benefit operation ireland puerto rico switzerland treatment provision certain litigation reserve nondeductible increase estimate contingent tax matter compared increase effective tax rate effective tax rate primarily decrease effective tax rate benefit operation ireland puerto rico switzerland provision million valuation allowance comprise million relate certain state foreign net defer tax asset million relate certain state foreign tax net operating loss tax credit carryforward partially offset million net release tax contingency reserve relate primarily settlement prior year tax matter determination company expect settlement ongoing tax litigation resolve company currently believe state net defer tax asset state net operating loss tax credit carryforward foreign net operating loss tax credit carryforward valuation allowance provide likely realize future low effective income tax rate result primarily low pretax income united states writeoff acquire process research development proportionately great tax benefit income earn low tax rate jurisdiction ireland puerto rico switzerland expense total cost expense percentage sale compare cost product sell percentage sale increase year compare principally increase sale lowermargin product otn largely offset increase sale high margin product pravachol cost product sell include million accelerate depreciation asset manufacturing facility north america expect closed end million charge asset impairment restructuring expense cost product sell include million reversal prior period reserve inventory writeoff relate cancel action include million restructuring expense marketing sell administrative expense percentage sale decrease marketing selling administrative expense increase million million primarily increase sale support abilify avaproavalide high pension cost high charge relate system infrastructure high insurance premium unfavorable foreign exchange impact principally relate euro marketing selling administrative expense percentage sale increase million million slight increase mainly high sale force expense result addition medical imaging business acquire october advertising promotion expense increase million million primarily result promotional support abilify reyataz launch plavix united states additional support inline product unfavorable foreign exchange impact europe advertising promotion expense decrease million million primarily result reduced spending metformin franchise vaniqa partially offset abilify product launch expense increase support plavix avaproavalide united states percentage sale advertising promotion expense increase company investment research development total million increase increase percentage sale decrease compare research development cost include million charge relate upfront payment license agreement million accelerate depreciation research facility research development spending dedicated pharmaceutical product decrease pharmaceutical sale compare respectively company focus research development activity fully realize value research development pipeline new priority include rebalancing drug discovery development increase support company latestage development pipeline close unnecessary facility include devote great resource ensure successful nearterm product launch increase company effort inlicense opportunity charge relate acquire inprocess research development million primarily relate milestone payment imclone system incorporate imclone erbitux million milestone payment imclone million expense acquire inprocess research development quarter remain million record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquire inprocess research development charge million include million relate dupont pharmaceutical acquisition million attributable imclone equity investment addition acquire inprocess research development include charge million million respectively license payment relate product approve marketing restructuring program implement downsize realign streamline operation order increase productivity reduce operating expense rationalize company manufacture network research facility administrative function action restructure program expect complete action restructure program substantially complete december result action company expect future annual benefit earning continue operation minority interest income taxis approximately million million million program respectively additional information restructuring item financial statementsnote restructuring item litigation charge net settlement income million compare million million fourth quarter company establish reserve liabilitie total million comprise million relation wholesaler inventory issue certain accounting matter million relation pharmaceutical pricing sale marketing practice addition company record charge million litigation matter recognize income million million income consist primarily million income patent defense cost reimbursement million litigation settlement income million settlement antitrust litigation involve vitamin manufacturer charge million primarily related buspar taxol propose settlement additional information litigation item financial statementsnote legal proceeding contingency equity net income affiliate million compare million million respectively equity net income affiliate principally relate company joint venture sanofi investment imclone increase equity net income affiliate primarily reflect high net income sanofi joint venture additional information equity net income affiliate item financial statementsnote alliance investment expense net income million million million respectively expense include net interest expense interest income foreign exchange gain loss royalty income gain loss disposal property plant equipment decrease expense primarily net gain interest rate swap increase expense compare principally high interest expense relate borrowing billion relate dupont pharmaceutical imclone transaction business segment company operate reportable segmentspharmaceutical otn nutritional healthcare otn previously include pharmaceutical segment meet quantitative threshold reportable segment outline sfas disclosure segment enterprise related information accordingly prior period reclassify conform current year presentation percent company sale segment follow total sale restate restate pharmaceutical oncology therapeutic network nutritional healthcare pharmaceutical worldwide pharmaceutical sale increase million reflect price increase volume increase increase foreign exchange domestic sale increase million primarily increase sale plavix pravachol franchise abilify total revenue glucovance paraplatin partly impact sale workdown nonconsignment wholesaler inventory partially offset decrease sale glucophage ir taxol primarily generic competition reyataz launch july million domestic sale international sale increase million include favorable foreign exchange impact primarily increase sale pravachol taxol plavix avaproavalide analgesic product europe partially offset price decline principally germany italy worldwide pharmaceutical sale decrease million reflect price decline volume decline foreign exchange impact domestic sale decline million primarily generic competition united states glucophage ir taxol buspar partially offset increase sale plavix addition product acquire dupont pharmaceutical acquisition complete october addition decrease domestic pharmaceutical sale impact buildup prior period inventory level wholesaler account consignment model subsequent workdown approximately million sale calculate net discount rebate adjustment recognize year end december reverse prior year international sale increase million significant foreign exchange impact primarily increase sale pravachol plavix europe taxol japan addition product acquire dupont pharmaceutical acquisition key pharmaceutical product sale include follow total revenue abilify primarily domestic alliance revenue company share net sale copromotion country otsuka pharmaceutical co ltd otsuka million schizophrenia agent introduce united states november december achieve weekly new prescription share antipsychotic market company receive approval supplemental new drug application snda abilify maintain stability patient schizophrenia announce submit snda abilify treatment acute mania patient bipolar disorder food drug administration fda abilify develop market bristolmyer squibb partner otsuka sale pravachol franchise increase include favorable foreign exchange impact million domestic sale increase million international sale increase include favorable foreign exchange impact million sale pravachol franchise increase million million sixmonth exclusivity extension grant april sale plavix platelet aggregation inhibitor increase include favorable foreign exchange impact million sale avaproavalide angiotensin ii receptor blocker treatment hypertension increase include favorable foreign exchange impact million sale plavix avaproavalide increase million million respectively sale plavix avaproavalide million million plavix avaproavalide cardiovascular product launch alliance bristolmyers squibb sanofi sale taxol paraplatin company leading anticancer agent increase include favorable foreign exchange impact million million significant foreign exchange impact respectively international sale taxol increase include favorable foreign exchange impact million lead strong sale japan france domestic sale taxol decrease million generic competition domestic sale paraplatin increase million taxol sale decrease million million paraplatin sale increase million million sale sustiva antiretroviral agent treatment human immunodeficiency virusautoimmune immunodeficiency virus hivaid increase include favorable foreign exchange impact million million prior year international sale sustiva increase include favorable foreign exchange impact million sustiva acquire dupont pharmaceutical october record sale million year monopril secondgeneration angiotensin convert enzyme ace inhibitor treatment hypertension increase sale include favorable foreign exchange impact reach million monopril sale increase million million glucophage franchise sale increase million compare decrease million million glucophage ir oral medication treatment noninsulin dependent type diabete see sale decrease million decline glucophage ir introduction generic metformin united states early glucophage ir sale decrease million million glucovance oral combination drug glucophage xr extend release tablet sale million million respectively compare sale million million respectively sale million million respectively sale zerit antiretroviral agent treatment hivaid decrease include favorable foreign exchange impact million primarily result decrease demand potential adverse effect zerit sale decrease million million sale videxvidex ec antiretroviral agent treatment hivaid increase include favorable foreign exchange impact million videxvidex ec sale increase million million sale serzone treatment depression decrease million result loss exclusivity labeling change indicate potential effect product serzone sale decrease million million follow table set forth comparison report net sale change estimate total prescription growth retail mail order customer certain company pharmaceutical prescription product estimate prescription growth amount base thirdparty datum provide ims health supplier market research pharmaceutical industry significant portion company domestic pharmaceutical sale wholesaler change report net sale differ prescription growth change net sale reflect underlie prescriber demand restate restate change change change change change change total total total net salesa prescriptionsb net salesa prescriptionsb net salesa prescriptionsb pravachol plavix avaproavalide sustiva na monopril glucovance glucophagexr zerit cefzil coumadin na videxvidex ec excess reflects change net sale dollar term include change average selling price wholesaler buy pattern b reflect change total prescription unit term base thirdparty datum earning minority interest income taxis million increase million primarily increase sale partially offset increase advertising product spend new exist inline product earning minority interest income taxis million million respectively increase mainly low earning result writeoff million acquire inprocess research development earning unfavorably affect high sale low margin product year impact generic competition glucophage ir taxol buspar united states oncology therapeutic network otn sale million increase prior year volume growth manufacturer price change sale increase million million otn sale account company net sale respectively earning minority interest income taxis million decrease slightly million million margin erosion investment system infrastructure nutritional nutritional sale million increase increase increase volume price increase partially offset decrease foreign exchange international sale increase include unfavorable foreign exchange impact million million domestic sale increase million million worldwide children nutritional sale increase include unfavorable foreign exchange impact million million result increase sale enfagrow primarily pacific region million worldwide infant formula sale increase million significant foreign exchange impact primarily increase sale enfamil company largestselle infant formula international sale enfamil increase million million significant foreign exchange impact domestic sale enfamil increase million million mead johnson nutritionals mead johnson continue leader infant formula market nutritional sale remain consistent sale billion reflect increase price offset decrease volume decrease foreign exchange worldwide infant formula sale decrease million primarily specialty infant formula business worldwide sale enfamil decrease million million worldwide children nutritional sale increase include unfavorable foreign exchange impact million million result increase sale enfagrow primarily pacific region million earning minority interest income taxis nutritional segment increase million million increase primarily increase sale enfamil united states earning minority interest income taxis nutritional segment decrease million million result increase promotional spending sale force expense related enfamil product line healthcare healthcare segment include convatec medical imaging business consumer medicine united states japan sales healthcare segment increase million million healthcare sale increase result increase volume increase change sell price increase foreign exchange sale segment increase million include million sale medical imaging purchase october dupont pharmaceutical acquisition healthcare sale increase result increase volume increase change sell price favorable foreign exchange impact healthcare sale business follow change restate restate dollar millions convatec medical imaging consumer medicine total healthcare excess increase convatec sale increase include favorable foreign exchange impact worldwide sale ostomy product million strong growth worldwide wound care product increase include favorable foreign exchange impact million foreign exchange favorable effect sale increase convatec sale increase worldwide sale ostomy product million strong growth worldwide wound care product increase million foreign exchange contribute sale increase increase medical imaging sale increase volume increase change sell price increase foreign exchange worldwide sale cardiolite increase million million medical imaging business purchase october dupont pharmaceutical acquisition steady decline sale consumer medicine million million million distributor reduce inventory level desirable level consumption excedrin consumer brand remain flat earning minority interest income taxis healthcare segment decrease million million primarily result unfavorable product mix inventory writeoff excedrin quicktab consumer medicine business earning minority interest income taxis segment increase million million primarily strong growth convatec business addition medical imaging business october geographic area company product available virtually country world large market united states france japan germany spain italy canada sales united states increase primarily increase sale plavix otn segment pravachol franchise abilify total revenue glucovance paraplatin sale increase partially offset continued impact generic competition united states glucophage ir taxol result loss exclusivity label change indicate potential effect serzone sale united states decrease primarily impact generic competition united states glucophage ir taxol buspar less extent buildup prior period inventory level wholesaler account consignment model subsequent workdown decrease partially offset increase plavix sale addition product acquire dupont dupont pharmaceutical pharmaceutical sale million company acquisition dupont pharmaceutical complete october information pharmaceutical prescriber demand refer table item businessbusiness segmentspharmaceutical segment set forth comparison change net sale estimate total prescription growth retail mail order customer certain company primary care pharmaceutical product sale europe middle east africa increase include increase foreign exchange result sale growth pravachol france taxol france germany spain italy analgesics france plavix germany spain avaproavalide italy sustiva spain favorable impact foreign exchange primarily euro sale europe middle east africa increase include increase foreign exchange result strong growth pravachol france united kingdom plavix spain addition dupont pharmaceutical product market region dupont pharmaceutical sale region million sale western hemisphere country increase include decrease foreign exchange primarily increase sale plavix canada unfavorable impact foreign exchange primarily mexico brazil venezuela sales western hemisphere country decrease include decrease foreign exchange unfavorable impact foreign exchange primarily brazil argentina underlie sale growth primarily increase sale plavix canada nutritional product mexico pacific region sale increase include increase foreign exchange result increase sale taxol japan increase sale enfagrow region sale pacific region increase include decrease foreign exchange product strong growth include taxol paraplatin japan nutritional product china indonesia development february fda approve biologics license application bla erbitux anticancer agent company develop partnership imclone erbitux injection use combination irinotecan treatment patient epidermal growth factor receptor egfr express metastatic colorectal cancer refractory irinotecanbase chemotherapy use single agent treatment patient egfr express metastatic colorectal cancer intolerant irinotecanbase chemotherapy accordance agreement company pay imclone million march milestone payment approval erbitux fda january company announce agree acquire acordis specialty fibre acordis privately hold company base united kingdom license patent right supply material convatec wound therapeutic line transaction subject regulatory approval receive transaction complete company expect record inprocess research development charge million million december company confirm mead johnson wholly own subsidiary company reach agreement novartis ag sell novartis adult nutritional business brand trademark patent intellectual property right million include million contingent product conversion million upfront payment supply agreement transaction close february pretax gain approximately million expect record quarter adult nutritional product record sale million december company lexicon genetic incorporate lexicon form broad alliance drug discovery development commercialization neuroscience field alliance design accelerate discovery development breakthrough therapy address significant unmet medical need psychiatry neurology company expensed initial payment million october company corgentech inc biotechnology company enter agreement jointly develop commercialize corgentechs ef decoy edifoligide treatment prevention vein graft failure follow coronary artery bypass graft peripheral artery bypass graft surgery product currently phase iii clinical trial fda grant fast track status indication company expensed initial payment million potential clinical regulatory milestone payment million arrangement profit sharing august pravigard pac buffer aspirin pravastatin sodium tablet launch united states july reyataz protease inhibitor treatment hivaid launch united states march company receive marketing approval reyataz eu august company enter licensing commercialization agreement flamel technologies sa develop market basulin control release unmodified human insulin develop oncedaily injection patient type type diabete basulin enter phase ii clinical development agreement company lead assume cost future development manufacturing effort basulin exclusive worldwide right product company expensed initial payment million october potential additional million clinical regulatory milestone payment time royalty payment product sale financial position liquidity capital resource cash cash equivalent marketable security total approximately billion december compare billion december approximately billion cash cash equivalent marketable security hold company foreign subsidiary company expect repatriate foreseeable future company expect cash generate operation borrowing capital market sufficiently cover cash need work capital capital expenditure dividend repatriation united states require additional tax provision reflect consolidated financial statement discussion matter critical accounting policiesincome taxis work capital increase billion december billion december primarily result increase marketable security decrease commercial paper outstanding partially offset increase accrue expense cash cash equivalent marketable security conversion workingcapital item borrowing expect fund nearterm operation cash cash equivalent december primarily consist dollar denominate bank deposit original maturity month marketable security december primarily consist dollar denominate float rate instrument aaaaaa credit rating nature instrument company consider reasonable expect fair market value significantly impact change interest rate liquidate cash short notice average interest yield cash cash equivalent december respectively interest yield marketable security average respectively longterm debt december denominate primarily dollar include japanese yen longterm debt million longterm debt increase billion december billion december primarily billion fix rate note billion float rate convertible debenture issue august october respectively proceed issuance repay shortterm borrowing fund cash need operation convertible debenture mature callable par time september issuer convertible company common stock share debenture share subject increase maximum share debenture base increase market price stock share plus antidilution certain adjustment interest payable quarterly annual rate equal month libor reset quarterly minus majority company debt fix rate company enter fixed float interest rate swap billion longterm debt interest expense million million million respectively commercial paper outstanding december commercial paper outstanding december million average interest rate average interest rate year end december international shortterm borrowing respectively current installment longterm debt respectively december company revolve credit facility total billion aggregate support domestic commercial paper program facility establish september august respectively syndicate lender extendable anniversary date consent lender revolve credit facility certain financial covenant company compliance december borrowing outstanding revolve credit facility december company unused shortterm line credit foreign bank million million december respectively july standard poor lower longterm credit rating company aa aa addition standard poor affirm short term rating april moodys investor service lower company longterm credit rating aa march moodys affirm prime shortterm credit rating company march standard poor place longterm shortterm rating company watch negative implication moodys longterm credit rating remain negative outlook net cash provide operating activity approximately billion billion billion increase attributable high net earning income tax payment primarily relate gain arise sale clairol business cash flow operation include pension contribution million million million respectively cash provide operation borrowing primarily past year pay dividend billion repurchase million share cost billion company invest billion past year capital expansion improve plant efficiency maintain superior research facility company purchase common stock company repurchase million million share common stock cost million million respectively bring total share acquire share repurchase program inception million share share repurchase program authorize company purchase common stock time time open market private transaction market condition permit program intend reduce increase share outstanding option exercise obtain share general corporate purpose employment level december remain constant compare prioryear level dividend declare common share year december company declare quarterly dividend common share indicate dividend year share company financial condition liquidity affect obligation milestone onetime payment outcome pende litigation investigation include challenge plavix patent information item financial statementsnote alliance investment note legal proceeding contingency contractual obligation payment period company contractual obligation december follow obligation expiring period later total year dollar million shortterm borrowing longterm debt capital lease operating lease purchase obligation imclone milestone payment standby letter credit longterm liability total obligation include shortterm borrowing company consolidated balance sheet december balance represent outstanding nominal longterm debt value addition company commit potential future milestone payment thirdpartie inlicense development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record company consolidate balance sheet discussion contractual obligation reference item financial statementsnote shortterm borrowing longterm debt note financial instrument note lease note pension postretirement benefit plan offbalance sheet arrangement march company imclone revise agreement reduce total payment million billion pursuant agreement company pay imclone million million million accordance agreement company pay imclone million march milestone payment approval erbitux fda pay additional million erbitux approve use second tumor type discussion company agreement imclone item financial statementsnote alliance investment recently issue accounting standard january financial accounting standard board fasb issue staff position fas accounting disclosure requirement relate medicare prescription drug improvement modernization act act act introduce prescription drug benefit medicare federal subsidy sponsor retiree health care benefit plan provide benefit actuarially equivalent medicare present detailed regulation necessary implement act include account federal subsidy issue company elect defer recognize effect act authoritative guidance account federal subsidy issue december staff securities exchange commission sec issue staff accounting bulletin sab revenue recognition supersede sab revenue recognition financial statement sab primary purpose rescind accounting guidance contain sab relate multiple element revenue arrangement supersede result issuance eitf accounting revenue arrangement multiple deliverable additionally sab rescind sec revenue recognition financial statement frequently ask question answer faq issue sab codify sec topic revenue recognition wording sab change reflect issuance eitf revenue recognition principle sab remain largely unchanged issuance sab initial adoption account pronouncement material effect company consolidate financial statement december fasb amend statement financial accounting standard sfas employer disclosure pension post retirement benefit amend statement revise employer disclosure pension plan postretirement benefit plan change measurement recognition plan require fasb statement employer account pension employer accounting settlement curtailment define benefit pension plan termination benefit employer disclosure postretirement plan pension revision include amend statement effective financial statement fiscal year end december company provide require disclosure item financial statementsnote pension postretirement benefit plan note legal proceeding contingency december fasb revised interpretation consolidation variable interest entity fin fin require variable interest entity consolidated company company subject majority risk loss variable interest entitys activity entitle receive majority entitys residual return fin require disclosure variable interest entity company require consolidate significant variable interest consolidation requirement fin revise apply immediately variable interest entity create january exist entity fiscal year interim period begin march certain disclosure requirement apply financial statement issue january regardless variable interest entity establish initial adoption account pronouncement material effect consolidated financial statement fasb issue sfas account certain financial instrument characteristic liabilitie equity sfas establishe standard issuer classifie measure certain financial instrument characteristic liability equity statement require issuer classify financial instrument scope liability initial adoption accounting pronouncement affect consolidated financial statement emerge issue task force reach consensus issue revenue arrangement multiple deliverable issue address certain aspect accounting vendor arrangement perform multiple revenue generating activity company revenue recognition policy conform requirement consensus initial adoption affect consolidated financial statement april fasb issue sfas amendment statement derivative instrument hedge activity sfas amend sfas require contract comparable characteristic account similarly specifically statement clarifie circumstance contract initial net investment meet characteristic derivative clarifie derivative contain finance component amend definition underlie conform interpretation guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin discuss amend certain exist pronouncement initial adoption account pronouncement material effect consolidated financial statement december fasb issue sfas accounting stockbase compensationtransition disclosure sfas amend sfas accounting stockbase compensation provide alternative method transition voluntary change fair value base method accounting stockbase employee compensation addition sfas amend disclosure requirement sfas require prominent disclosure annual interim financial statement method accounting stockbase employee compensation effect method report result provision sfas effective financial statement year end december sfas material impact company consolidate financial statement adoption standard require company change company plan change fair value base method accounting stockbased compensation november fasb issue fin fin require guarantor recognize liability inception guarantee fair value obligation undertake issuing guarantee include detailed disclosure respect guarantee type contract company enter meet scope interpretation financial performance standby letter credit behalf wholly own subsidiary fin effective guarantee issue modify december initial adoption accounting pronouncement material effect company consolidate financial statement retirement benefit plan description company certain subsidiary define benefit pension plan define contribution plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan principal define contribution plan bristolmyer squibb saving investment program approximately total company define benefit pension plan asset liability hold plan asset plan hold single trust common asset allocation specify reference section total company plan plan international plan benefit company define benefit pension plan base primarily year credit service participant compensation asset company define benefit plan consist primarily equity fixedincome security december fair market value plan asset company define benefit plan increase million million december plan asset allocate equity security compare end fix income security compare end private equity investment compare end bristolmyer squibb common stock represent asset plan end company provide comprehensive medical group life benefit substantially retiree elect participate company comprehensive medical group life plan asset allocation postretirement plan identical asset allocation describe define benefit pension plan accrual account significant assumption consistent requirement sfas employer accounting pension company account pension benefit accrual method recognize pension expense payment benefit retiree accrual method accounting pension benefit necessarily require actuarial assumption concern future event determine timing benefit payment company key assumption calculate cost pension benefit discount rate rate compensation increase expect longterm rate return plan asset company consultation actuary evaluate key actuarial assumption assumption calculate cost pension benefit retirement turnover mortality rate base expectation actual experience appropriate determine assumption december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning addition assumption materially affect accumulate benefit obligation future cash fund actual result give year differ estimate economic factor assume discount rate company determine future pension obligation plan base indices aa aaarate corporate bond indice high quality corporate bond select reflect weightedaverage remain period benefit payment assume rate compensation increase company determine future pension obligation reflect estimate change actual future compensation level general price level productivity seniority factor net pension expense company define benefit pension plan include earning minority interest income taxis million compare million plan pension expense determine assumed discount rate assume rate compensation increase present value benefit obligation december plan determine assumed discount rate assume discount rate determine plan pension expense reduce expense increase approximately million assumed rate compensation increase determine plan pension expense reduce expense decrease approximately million assumed discount rate determine accumulate benefit obligation december reduce accumulate benefit obligation increase million plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million actual rate return earn plan asset year follow year return year return discuss gaap provide difference expect actual return recognize average future service employee december company lower assume discount rate plan assume rate compensation increase raise follow review recent experience compensation assume increase scale different rate different age rate disclose december single rate age produce present value benefit obligation methodology disclosure calculate rate december rate december reduction discount rate increase assume rate compensation increase effect increase present value benefit obligation accordingly effect increase pension expense addition company revise base review experience assumption active mortality revision effect increase present value benefit obligation accordingly effect increase pension expense december company lower assume discount rate plan reflect decline yield high quality corporate bond assume rate compensation decrease reflect expectation low inflation future consistent reduction assume discount rate reduction assume discount rate increase present value future benefit obligation accordingly effect increase plan pension expense contrast reduction assume rate compensation increase decrease present value benefit obligation accordingly effect decrease plan pension expense addition company revise base change expectation future termination retirement retirement turnover assumption revision decrease present value benefit obligation pension expense follow year strong performance global equity market fall sharply sp decline cumulative reverse sp rose company reduce expect rate return plan asset december maintain company expect net pension expense define benefit pension plan include earning minority interest income taxis approximately million high million reflect thing decrease assume discount rate increase assume rate compensation increase decrease marketrelate value asset company define benefit pension plan rise global equity market improve fund status plan difficult year investment gain loss recognize marketrelated value asset period year negative impact period feel follow put upward pressure pension expense company assume discount rate expect longterm rate return plan asset calculate cost pension benefit cost postretirement benefit case discount rate december rate pension benefit versus postretirement benefit reflect short duration postretirement liabilitie health care cost retiree population assume increase trend expect increase year actual cost higher assume likely significant upward pressure company expense retiree health care december president bush sign law medicare prescription drug improvement modernization act follow guidance fasb staff position fas company elect defer recognition effect act accumulate postretirement benefit obligation net periodic postretirement benefit cost reflect effect act plan specific authoritative guidance account federal subsidy pende fasb guidance issue require change previously report information delay recognition actuarial gain loss december unrecognize net actuarial loss company define benefit plan million million respectively base fair market value plan asset unrecognize net actuarial loss reflect decline fair market value plan asset reduction weightedaverage discount rate sfas provide delay recognition actuarial gain loss include amount arise change estimate plan benefit obligation change assume discount rate difference actual expect return plan asset assumption change sfas require unrecognized net actuarial gain loss determine base marketrelated value plan asset differ fair market value calculate value recognize change fair value systematic rational manner year amortize pension income expense year extent unrecognize net actuarial loss gain exceed great project benefit obligation marketrelated value plan asset begin year net gain loss recognize pension income expense prospectively period approximate average remain service period active employee expect receive benefit plan approximately year extent offset loss gain subsequent year december unrecognize net actuarial loss determine base marketrelated value plan asset million exceed great project benefit obligation market relate value plan asset million december unrecognized net actuarial loss determine base marketrelated value plan asset million exceed great project benefit obligation market relate value plan asset million offset future unrecognized gain high discount rate higher expect return plan asset amortization million unrecognized loss expect increase pension expense follow year approximately million year reflect high expense expect event fair market value pension plan asset particular plan accumulate benefit obligation plan yearend gaap require additional minimum liability circumstance reduction stockholder equity establishment intangible asset december fair market value company define benefit pension plan asset million relate accumulate benefit obligation million company recognize additional minimum liability million cumulative million december offset million charge comprehensive income include stockholder equity december fair market value company define benefit pension plan asset million relate accumulate benefit obligation million company recognize additional minimum liability million cumulative million december offset creation million intangible asset million charge comprehensive income include stockholder equity plan funding company fund policy define benefit plan contribute amount provide current service fund past service liability company contribute define benefit plan million million respectively critical accounting policy company prepare financial statement conformity accounting principle generally accept united states preparation financial statement conformity gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period company critical accounting policy important company financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate company believe follow represent critical accounting policy summary company significant accounting policy include critical accounting policy discuss item financial statementsnote accounting policy management company independent accountant discuss company critical accounting policy audit committee board director revenue recognition company accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management company recognize revenue sale substantially risk reward ownership transfer customer case certain transaction pharmaceuticals wholesaler account consignment model gaap revenue recognize substantially risk reward ownership transfer case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net discount rebate sale allowance accrual return involve significant estimate judgment consignment inventory long subject incentive arrangement later inventory sell wholesaler customer fifo basis company estimate inventory wholesaler defer revenue consign inventory base project prescription demandbase sale product company analysis thirdparty information include information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum company internal information company estimate subject inherent limitation estimate rely thirdparty datum certain thirdparty information form estimate reflect limitation acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant entitle asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital impairment longlive asset accordance sfas accounting impairment disposal longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value goodwill evaluate annually impairment accordance sfas goodwill intangible asset sfas require goodwill test impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value estimate future cash flow base reasonable supportable assumption projection require management judgment change key assumption company business prospect change market condition result impairment charge equity investment company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider accounting principle board opinion equity method accounting investment common stock set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment company investment imclone subject accounting item financial statementsnote alliance investment discussion company investment imclone retirement benefit company pension plan postretirement benefit plan account actuarial valuation require sfas employer account pension sfas employer account postretirement benefit pension company consider accounting retirement plan critical management require significant subjective judgment number actuarial assumption include discount rate salary growth longterm return plan asset retirement turnover health care cost trend rate mortality rate depend assumption estimate pension postretirement benefit expense vary range outcome material effect report earning addition assumption materially affect accumulate benefit obligation future cash funding detailed discussion company retirement benefit retirement benefit item financial statementsnote pension postretirement benefit plan restructure downsize streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate result adjustment earning contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder suit product liability environmental liability tax matter accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate discussion contingency item financial statementsnote income taxis note legal proceeding contingency income taxis december taxis provide approximately billion undistributed earning foreign subsidiary company invest expect invest undistribute earning indefinitely future earning repatriate united states company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company evaluate need defer tax asset valuation allowance assess likely realize defer tax asset future assessment valuation allowance require require significant judgment include forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment addition company operation tax jurisdiction locate area world subject audit jurisdiction tax audits nature complex require year resolve accrual tax contingency require management estimate judgment respect ultimate outcome tax audit actual result vary estimate outlook company expect growth opportunity exclusivity challenge year estimate reduction net sale range billion level product lose lose exclusivity protection specifically metformin franchise united states taxol europe monopril united states canada pravastatin certain country europe paraplatin united states serzone united states sale rise result high base generic competition develop expect increase expect level exclusivity loss addition impact exclusivity loss paraplatin anticipate occur primarily accelerate anticipated sixmonth extension exclusivity protection base pediatric study obtain april amount sale reduction exclusivity loss realization particular period eventual level remain sale revenue uncertain dependent level sale time exclusivity protection end time degree development generic competition speed approval market entry impact factor subject uncertainty company estimate incremental exclusivity loss measure net sale level time exclusivity lose billion billion year company believe revenue loss offset growth revenue result growth company inline product include plavix avaproavalide sustiva growth recently launch exclusive product abilify reyataz growth recently fda approve product erbitux introduction latestage pipeline product abatacept entecavir muraglitazar approve thirtysix month begin contribute significantly additionally otn sale growth expect continue belief subject competitive factor include relate pravachol adverse determination occur respect plavix patent litigation item businesscompetition item financial statementsnote legal proceeding contingency addition assurance company obtain require regulatory approval latestage pipeline product company expect result product mix pressure company margin product lose exclusivity protection carry high margin product expect grow sale pravachol statin cholesterol company large product net sale product beginning lose exclusivity market loss exclusivity expect rate decline market share accelerate recent clinical study company historically review continue review cost base decision take result review result restructuring charge later year future period time company expect invest inline product research development pipeline particularly latestage product reflect earning guidance external development licensing remain important element company strategy potential cost impact transaction enter future build company plan guidance respect earning company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity additional discussion matter item financial statementsnote legal proceeding contingency company expectation future sale growth describe include substantial expect increase sale plavix net sale approximately billion composition matter patent plavix expire currently subject litigation united states similar proceeding involve plavix institute outside united states company continue believe patent valid infringe alliance partner patentholder sanofi vigorously pursue case possible time reasonably assess outcome litigation adverse determination litigation time potential generic competition plavix generic competition occur company believe unlikely occur loss market exclusivity plavix subsequent development generic competition material company sale plavix result operation cash flow material financial condition liquidity actual result differ materially experience describe factor affect expectation describe cautionary factor affect future result cautionary factor affect future result annual report include document incorporate reference write oral statement company make time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year possible predict identify factor include limited follow new government law regulation health care reform initiatives united states state federal level country ii change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available united states certain foreign country iv new law regulation judicial decision affect pricing marketing jurisdiction v change intellectual property law competitive factor new product develop competitor low price superior performance feature competitive bristolmyer squibb current product ii generic competition company product mature patent expire product iii technological advance patent attain competitor iv problem licensor supplier distributor v business combination company competitor major customer difficulty delay inherent product development manufacturing sale product appear promise development fail reach market number reason include efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture ii failure product achieve maintain commercial viability iii seizure recall product iv failure obtain imposition limitation use loss patent intellectual property right v failure company vendor supplier comply current good manufacturing practice application regulation quality assurance guideline lead temporary manufacturing shutdown product shortage delay product manufacture vi manufacturing distribution problem legal difficulty include lawsuit claim proceeding investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition include intellectual property dispute ii adverse decision litigation include product liability commercial case iii inability obtain adequate insurance respect type liability iv recall pharmaceutical product force closing manufacture plant v government investigation include relate wholesaler inventory financial restatement product pricing promotion vi claim assert violation security antitrust federal state pricing law vii environmental matter viii tax liability assurance increase scope matter future lawsuit claim proceeding investigation material increase pricing pressure worldwide include rule practice manage care group institutional governmental purchaser judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement pricing general fluctuation buy pattern inventory level major distributor retail chain trade buyer result seasonality pricing wholesaler buying decision include effect incentive offer company wholesaler inventory management policy include workdown change wholesaler inventory level factor great expect cost difficulty include unanticipated effect difficulty acquisition disposition event include obtain regulatory approval connection evolve business strategy legal defense cost insurance expense settlement cost risk adverse decision relate litigation change advertise promotional spend category spending affect sale change product mix affect margin change companys structure operation revenue cost staff efficiency result acquisition divestiture merger alliance restructuring strategic initiative economic factor company control change business economic condition include limited change interest rate fluctuation foreign currency exchange rate change business political economic condition political social instability military armed conflict nationalization asset debt payment moratorium restriction commerce actual threaten terrorist attack united states part world relate military action change accounting standard promulgate fasb sec american institute certify public accountant require adjustment financial statement capacity efficiency reliability security potential breakdown invasion destruction interruption information system reliance company vendor partner party meet contractual regulatory obligation relation arrangement company result clinical study relate company competitor product company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose gain loss hedge transaction offset gain loss underlying exposure hedge ineffective portion hedge report earning occur foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure relation dollar euro japanese yen canadian dollar mexican peso table summarize company outstanding foreign exchange contract december fair value foreign exchange contract base yearend currency rate blackschole model case option contract fair value option contract forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weight average notional fair strike price value maturity dollar million currency rate foreign exchange forward australian dollar brazilian real british pound canadian dollar euro japanese yen south african rand swedish krona swiss franc total contract december company hold option contract aggregate notional fair value million million respectively contract grant right sell euros canadian australian dollar company hold forward contract aggregate notional million fair value liability million contract primarily relate exposure euro company use derivative instrument interest rate risk management policy derivative instrument include interest rate swap subject fairvalue hedge accounting treatment company execute fix float interest rate swap convert billion company fix rate debt pay variable rate debt year end december company recognize net reduction interest expense million reflect benefit lower float rate obtain swap agreement sfas require revaluation fair value swap contract underlie debt hedge swap contract underlie debt revalue result increase current asset longterm debt million swap contract generally hold maturity speculative purpose follow table summarize interest rate swap outstanding december dollar millions notional underlie debt variable rate receive maturity fair value interest rate contract swap associate note month libor swaps associate note month libor swaps associate note month libor swaps associate note month libor follow table summarize interest rate swap outstanding december dollar millions notional interest rate contract underlie debt variable rate receive maturity fair value swap associate note month usli bor swap associate note month libor estimate change interest rate structure material impact company consolidate financial position result operation cash flow company outstanding interest rate foreign currency swap relate japanese yen note aggregate fair value instrument december million million respectively company million million longterm debt outstanding december respectively item financial statementsnote shortterm borrowing longterm debt note financial instrument additional information company maintain cash cash equivalent marketable security financial institution order limit exposure financial institution financial institution headquarter primarily north america europe bristolmyers squibb company consolidate statement earning million share datum item financial statement supplementary datum year end december restate restate earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure item litigation charge net gain sale businessesproduct line asset impairment charge investment imclone equity net income affiliate expense net total expense earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation discontinue operation net earning net gain disposal net earning earning common share basic earning continue operation discontinue operation net earning net gain disposal net earning dilute earning continue operation discontinue operation net earning net gain disposal net earning average common share outstanding basic dilute dividend declare common share accompany note integral financial statement bristolmyers squibb company consolidate statement comprehensive income retain earning dollar million restate restate comprehensive income net earning comprehensive income foreign currency translation net tax benefit defer loss derivative qualify hedge net tax benefit minimum pension liability adjustment net tax benefit available sale security net taxis total comprehensive income comprehensive income retain earning retain earning january net earning cash dividend declare zimmer common stock dividend retain earning december accompany note integral financial statement bristolmyers squibb company consolidate balance sheet dollar million december restate asset current asset cash cash equivalent marketable security receivables net allowance inventory include consignment inventory defer income taxis net valuation allowance prepaid expense total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance asset total asset liability current liability shortterm borrowing account payable accrue expense accrue rebate return foreign income taxis payable dividend payable accrue litigation liability defer revenue consign inventory total current liability liabilitie longterm debt total liability commitment contingency stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share issue capital excess par value stock restrict stock accumulate comprehensive loss retain earning cost treasury stock common share total stockholder equity total liability stockholder equity accompany note integral financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december restate restate cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization provision defer income taxis acquire inprocess research development litigation charge asset impairment charge investment imclone provision restructure item gain sale businessesproduct line include discontinued operation loss gain disposal property plant equipment equity net income affiliate impairment charge asset writeoff litigation settlement payment net receipt minority interest net distribution tax pension contribution change operate asset liability receivables inventory prepaid expense asset defer revenue consign inventory account payable accrue expense foreign income taxis payable liability net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software proceed disposal property plant equipment proceed sale businessesproduct line proceed sale clairol purchase dupont pharmaceutical clairol dupont pharmaceutical divestiture acquisition cost investment company purchase trademark patent license net cash investing activity cash flow financing activity shortterm borrowing net repayment longterm debt borrowing longterm debt repayment issuance common stock stock plan purchase treasury stock dividend pay net cash provide financing activity effect exchange rate cash increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral financial statement bristolmyers squibb company note consolidated financial statement note accounting policy note consolidated financial statement certain prior period prior period comparison reflect balance amount restate basis information restatement note restatement previously issue financial statement year end december basis consolidation consolidate financial statement include account bristolmyer squibb company bms company bristolmyers squibb control majority own subsidiary intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation include reclassification amount relate equity net income affiliate net minority interest net taxis present separate line consolidate statement earning investment use estimate preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability estimate apply revenue recognition policy accounting retirement postretirement benefit include actuarial assumption actual result differ estimate result revenue recognition company recognize revenue substantially risk reward ownership transfer customer case certain sale nutritional healthcare segment certain nonus business pharmaceutical segment revenue recognize date receipt purchaser revenues reduce time sale reflect expect return estimate base historical experience additionally provision time sale discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis company estimate inventory wholesaler defer revenue consign inventory base project prescription demandbase sale product company analysis thirdparty information include information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum company internal information company estimate subject inherent limitation estimate rely thirdparty datum certain thirdparty information form estimate reflect limitation sale rebate return accrual medicaid rebate accrual million million december respectively manage healthcare rebate accrual million million december respectively rebate accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability accrual record base estimate proportion record revenue result rebate return prime vendor chargeback accrual establish similar manner record reduction account receivable million million december respectively bristolmyer squibb company note consolidated financial statement continue note accounting policy continue income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize company record provision income taxis undistribute earning foreign subsidiary expect repatriate foreseeable future company establish liability possible assessment tax authority result know tax exposure amount represent reasonable provision taxis ultimately expect pay need adjusted time information know cash cash equivalent cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value marketable security company account marketable security accordance statement financial accounting standard sfas account certain investment debt equity security company determine appropriate classification marketable security availableforsale time purchase december company investment marketable security report fair value unrealize gain loss report component accumulate comprehensive income loss stockholder equity amortize cost debt security adjust amortization premium accretion discount date purchase maturity amortization include interest income addition deduction coupon interest earn investment company follow investment manager method determine cost basis computing realize gain loss sale availableforsale security average cost method realize gain loss include income expense marketable security classify available sale record cost approximate fair value inventory valuation inventory generally state average cost excess market capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry value depreciable asset recoverable impairment longlive asset effective january company adopt provision sfas accounting impairment longlive asset adoption sfas material effect consolidated financial statement company sfas establish accounting impairment longlive tangible intangible asset goodwill disposal segment business pursuant sfas company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value bristolmyer squibb company note consolidated financial statement continue note accounting policy continue capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software net accumulate amortization include asset million million december respectively investment january company adopt financial accounting standard board fasb interpretation fin interpretation consolidation variable interest entity interpretation arb fin clarifie application accounting research bulletin arb consolidated financial statement certain entity equity investor characteristic control financial interest sufficient equity risk entity finance activity additional subordinate financial support party entity know variable interest entity vie fasb issue revision fin fin r december fin r effective interim period end march new exist vie adoption fin effect company financial statement entity meet definition vie fin company account entity provision accounting principle board apb opinon number equity method accounting investment common stock require company consolidate majority own subsidiary ability exercise control company account own company ability exercise significant influence equity method accounting company share net income loss equity investment include equity net income affiliate consolidate statement earning company periodically review equity investment impairment adjust investment fair value decline market value deem temporary company record asset impairment charge million otherthantemporary decline market value imclone system incorporate imclone longterm investment security comprise marketable equity security security investment market value readily available include asset marketable equity security classify availableforsale report fair value fair value base quote market price end report period security investment market value readily available carry cost unrealize gain loss report net relate tax effect component accumulate comprehensive income loss stockholder equity sell time sale gain loss calculate specific identification method recognize incomeexpense loss recognize income decline market value deem temporary goodwill intangible asset company adopt sfas goodwill intangible asset january certain provision adopt july respect amortization goodwill arise acquisition june sfas address initial recognition measurement intangible asset acquire outside business combination recognition measurement goodwill intangible asset subsequent acquisition new rule goodwill long amortize subject annual impairment test connection accounting change goodwill result company acquisition dupont pharmaceutical business dupont pharmaceutical investment imclone amortize goodwill arise business acquisition prior july amortize straightline basis period range year goodwill amortize effective january goodwill amortization expense million accordance sfas goodwill test impairment adoption new standard annually sfas require goodwill test impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value company complete goodwill impairment assessment indicate impairment goodwill bristolmyers squibb company note consolidated financial statement continue note accounting policy continue intangible asset consist patent trademark technology license amortize straightline basis useful life range year sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value intangible asset evaluate impairment accordance sfas describe impairment longlive asset product liability accrual product liability record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability record undiscounted basis probable recovery realize classified reduction litigation charge consolidate statement earning contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include product liability environmental liability tax matter accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate discussion contingency reference note income taxis note legal proceeding contingency derivative financial instrument derivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument speculative purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize charge credit earning derivative designate cash flow hedge effective portion change fair value derivative record comprehensive income loss subsequently recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earning company designate assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company immediately recognize gain loss designate hedge financial instrument consolidate statement earning shipping handling cost company typically charge customer shipping handle cost shipping handling cost include marketing sell administrative expense million million million respectively advertising cost advertising cost expense incur advertising expense million million million respectively milestone payment company time time enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party result alliance company obligate payment alliance partner contingent achievement certain predetermine criterion milestone achieve prior marketing approval product payment expense research development product approval additional milestone capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability event change circumstance indicate carrying amount recoverable bristolmyer squibb company note consolidated financial statement continue note accounting policy continue acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant entitle asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur earning share basic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option convertible instrument stock compensation plan company apply apb opinion accounting stock issue employee relate interpretation accounting stockbase compensation plan company recognize compensation expense stock option grant plan exercise price option date grant equal fair market value date grant restrict stock company recognize compensation expense straightline basis period restriction expire follow table summarize company result pro forma basis record compensation expense base fair value grant date award plan consistent methodology prescribe sfas accounting stockbase compensation restate restate dollar million share datum net earning report deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma basic earning share report pro forma diluted earning share report pro forma note stockholder equity additional information bristolmyer squibb company note consolidated financial statement continue note restatement previously issue financial statement year end december company restate consolidated balance sheet december consolidate statement earning cash flow comprehensive income retain earning year end december restatement affect period prior impact restatement prior period reflect adjustment retain earning january addition restatement impact second quarter restate amount quarter comparable interim period present note select quarterly financial datum unaudite restatement correct certain company historical accounting policy conform gaap ii correct certain error application gaap set forth restatement adjustment include restatement previously issue financial statement year end december error mean apb opinion accounting change follow table present impact restatement adjustment describe net earning year end december retain earning january net earning retain year end earning december january dollars millions report wic rebate accrual good transit net sale adjustment international pension employee benefit plan accrual intercompany account marketing sell administrative adjustment intercompany foreign exchange gain loss restatement item adjustment minority interest net taxis provision income taxis restate adjustment net sale relate adjustment cost product sell wic rebate accrual historically company accrue rebate woman infant child wic program date coupon issue states error application gaap require accrual date sale product company correct policy accrue wic rebate date sale good transit company correct error application gaap time revenue recognition certain sale mead johnson nutritionals mead johnson unit healthcare unit certain nonus pharmaceutical unit company previously record revenue product sell date shipment record revenue base term sale date receipt purchaser net sale adjustment company correct error accounting manage health care sale rebate accrual amount initially record connection company previous restatement company restate certain sale transaction certain asia business unit revenue recognize error prior transfer substantially risk reward ownership existence right return available purchaser product company erroneously fail adjust timely basis accrual sale return charge back deduction sale product divest division prior divestiture require gaap adjustment earning continue operation minority interest income taxis international pension employee benefit plan accrual historically company erroneously account certain international employee benefit plans cash nongaap method base belief impact apply accrual method require gaap immaterial company actuarial analysis perform large plan determine understate benefit liability plan company account pension bristolmyer squibb company note consolidated financial statement continue note restatement previously issue financial statement year end december continue employee benefit plan accrual method addition company fail require accrual international employee benefit plan misapplication gaap intercompany account company determine certain unreconciled intercompany account payable receivable aggregate net balance million write prior january marketing sell administrative adjustment company record number adjustment respect marketing sell administrative expense company determine error application historical accounting policy accrue earn vacation take company determine properly record expense training operational support relate contract party period incur company write certain account adequate documentation support existence company write reserve postemployment benefit pension retain error certain divested business company incorrectly capitalize certain cost relate internally develop software misapplication gaap company fail adjust certain expense reserve timely basis actual expense incur require gaap company correct number small immaterial error application gaap intercompany foreign exchange gain loss historically company defer gain loss certain intercompany foreign exchange loan transaction recording gain loss accumulate comprehensive loss company consolidate balance sheet error application gaap require intercompany transaction longterm investment settlement plan foreseeable future foreign currency transaction gain loss include determine net income company correct policy comply gaap restatement item company foreign subsidiary operate jurisdiction hyperinflationary currency respect company record restatement adjustment correct error relate accounting defer tax asset liabilitie valuation allowance result company record foreign exchange gain loss respect defer tax asset error company erroneously overaccrue expense relate certain grant complete fail adjust accrual actual amount expense incur life grant company fail writeoff unreconciled account relate acquisition dupont pharmaceutical company fail adjust certain expense reserve timely basis actual expense incur require gaap company correct number small immaterial error application gaap adjustment minority interest net taxis company record duplicate defer tax net asset error relate tax attribute certain partnership entity sanofisynthelabo sanofi own majority control interest adjustment provision income taxis contingency reserve certain instance period restate company error record reserve tax contingency company believe inappropriate adjustment tax contingency reserve company complete review able determine error tax contingency reserve correct restatement relate inappropriate account federal state tax item company identify number error relate current deferred federal state taxis correspond current defer tax expense error include establish defer tax asset extent necessary corresponding valuation allowance net operating loss tax credit carryforward ii apply misapply asset liability approach defer taxis require gaap iii consider relevant information date issuance financial statement iv timely adjust difference tax provision file tax return foreign tax item company identify number error relate current deferred foreign taxis correspond tax expense error include establish defer tax asset extent necessary corresponding valuation allowance net operating loss tax credit carryforward ii apply misapply asset liability approach defer taxis require gaap iii consider information available date issuance financial statement iv timely adjust file tax return v accounting income taxis certain jurisdiction cash basis bristolmyer squibb company note consolidated financial statement continue note restatement previously issue financial statement year end december continue follow table present impact restatement adjustment describe provision income taxis earning minority interest income taxis provision income taxis previously report contingency reserve tax item nonus provision income taxis restate follow table present impact income tax restatement adjustment describe company consolidated balance sheet december contingency tax reserve item asset defer income taxis current deferred income taxis noncurrent liability accrue liability foreign income taxis payable adjustment cash cash equivalent classification company determine certain investment cash management program erroneously classify cash equivalent consolidate balance sheet december statement cash flow fiscal year respectively approximately billion billion investment hold company reflect cash cash equivalent companys consolidated balance sheet december respectively company believe investment highly liquid maturity investment exceed month previous presentation cash cash equivalent error company restate prior period present investment marketable security restatement adjustment company consolidate balance sheet december decrease cash cash equivalent approximately billion restatement adjustment statement cash flow increase net cash investing activity year end december approximately billion billion respectively adjustment expense net classification table present restatement charge credit certain amount classified error reclassify restatement expense net appropriate line item consolidate statement earning year end december year end december dollar million total adjustment expense net net sale rebate accrual adjustment cost product sell royalty expense product liability expense royalty receivable writeoff adjustment neta marketing sell administrative amortization capitalize software restrict stock grant amortization neta advertising product promotion neta research development reimbursement clinical study expenditure neta equity net income affiliate imclone share loss certain item include net reclassification amount error mean apb opinion accounting change amount reclassify conform current year presentation bristolmyers squibb company note consolidated financial statement continue note restatement previously issue financial statement year end december continue follow table present impact restatement adjustment company previously report result condense basis previously previously report restate report restate dollar million share datum statement earning net sale total cost expense earning continue operation discontinue operation net lossearning net gain disposal net earning basic earning common share continue operation discontinue operation net earning net gain disposal net earning dilute earning common share continue operation discontinue operation net earning net gain disposal net earning balance sheet december asset current asset cash cash equivalent marketable security current asset total current asset asset total asset liabilitie current liability liabilitie longterm debt total liability stockholder equity total liability stockholder equity bristolmyers squibb company note consolidated financial statement continue note alliance investment sanofisynthelabo company agreement sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicate treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operate framework geographic territory america australia europe asia territory partnership form manage central expense market research development royalty supply finish product individual country country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place company act operating partner territory cover america principally united states canada puerto rico latin american countries australia own majority control interest territory company consolidate country partnership result territory record sanofis share result minority interest net taxis million million million company record sale territory comarkete country germany italy spain greece million million million sanofi act operating partner territory cover europe asia own majority financial control interest territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million company sanofi form alliance copromotion irbesartan company contribute irbesartan distribution right united states sanofi pay company total million company account transaction sale interest license defer amortize million income expect useful life license approximately year company amortize income million million otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify aripiprazole treatment schizophrenia total milestone payment otsuka december million million expense acquire inprocess research development million capitalize payment amortize remain life agreement approximately year company begin copromote product otsuka united states puerto rico november company copromote product european country marketing approval receive european authority revenue earn otsuka ship product title pass customer company record alliance revenue share net sale copromotion country record expense relate product company exclusive right sell abilify number country europe latin america asia countries sale commence company record net sale relate cost sale company record revenue abilify million million imclone november company purchase million share imclone share million represent approximately imclone share outstanding prior company commencement public tender offer imclone share transaction account equity method accounting imclone biopharmaceutical company focus develop targeted cancer treatment include growth factor blocker cancer vaccine antiangiogenesis therapeutic equity investment imclone strategic agreement company imclone include arrangement codevelop copromote cancer drug erbitux series payment originally total billion company pay imclone milestone payment million december imclone announce food drug administration fda refuse accept filing biologic license application bla submit imclone erbitux bla submit gain marketing approval treat irinotecanrefractory colorectal carcinoma march agreement imclone revise reduce total payment million billion revise agreement company pay imclone million march million march million march approval erbitux fda additional million achievement second milestone million pay imclone march million expense inprocess research development quarter remain million record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone revise agreement company pay imclone distribution fee base flat rate bristolmyer squibb company note consolidated financial statement continue note alliance investment continue product net revenue north america company purchase commercial requirement bulk erbitux imclone price equal actual manufacturing cost plus term revise agreement continue fourth quarter company record pretax charge approximately million comprise million writeoff acquire process research development relate equity investment million writeoff portion million milestone payment remain million million milestone payment record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquire inprocess research development charge relate oncology research project phase later stage development research project erbitux determine identify research project area technological feasibility establish alternative future use project fda approval date year time company expect project begin generate cash flow cost complete project estimate million research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require obtain fda approval purchase price allocation result million patent technology intangible asset amortize weightedaverage useful life year approximately million goodwill amortize million pay equity investment million milestone payment million million expense acquire process research development remain million record equity investment additional million add investment primarily acquisition cost result carry value million december quarter company record pretax charge earning million temporary decline market value imclone base decline value imclone share fair value equity investment imclone record impairment determine base market value imclone share september total equity investment imclone december million compare million december share basis carry value imclone investment closing market price imclone share december respectively compare respectively december closing market price imclone share march share company record million net loss share imclone loss include million loss million relate imclone restatement result final reporting year quarter result company record million net loss share imclone loss amortization previously capitalize milestone payment company record share result equity net income affiliate consolidate statement earning february fda approve resubmitte bla erbitux erbitux treatment patient epidermal growth factor receptor egfr express metastatic colorectal cancer fail irinotecanbase regimen combination irinotecan monotherapy patient intolerant irinotecan bristolmyers squibb company note consolidated financial statement continue note alliance investment continue summary financial information follow summarize financial information company equity investment imclone joint venture sanofi europe asia dollar millions revenue gross profit net income current asset noncurrent asset current liability noncurrent liability information include imclone datum date investment november bristolmyers squibb company note consolidated financial statement continue note restructure item activity company record pretax restructuring charge million relate downsize streamline worldwide operation rationalization worldwide manufacturing operation charge million primarily relate employee termination benefit approximately employee include manufacture administrative sale personnel europe north america asia central america item million relate primarily relocation expense result consolidation research facility charge partially offset adjustment change estimate prior period reserve million principally higher anticipate proceed disposal asset reduce separation cost company expect complete restructuring activity addition company record million asset impairment accelerate depreciation relate rationalization manufacturing operation cost product sell follow table present detail provision restructure item operating segment type company allocate restructuring charge business segment employee employee termination exit termination benefit cost item total pharmaceutical healthcare subtotal reduction reserve change estimate provision restructure item company record million research development relate upfront payment licensing agreement allocate business segment activity company record pretax restructuring charge million relate reduction elimination nonstrategic research effort consolidation research facility workforce reduction downsize streamline worldwide operation charge million relate employee termination benefit approximately employee include research manufacturing sale administrative personnel million represent asset writedown include million impairment charge company investment deltagen million exit cost closure facility relate expense charge offset adjustment prior period restructure reserve million million lower expect separation cost million higher anticipate proceed disposal asset previously write restructure million project cancel addition million adjustment cost product sell reflect reversal inventory reserve associate cancel project company substantially complete restructuring activity addition million accelerate depreciation relate plan shutdown research facility united states include research development expense million inventory writeoff associate project include cost product sell bristolmyers squibb company note consolidated financial statement continue note restructure item continue follow table present detail provision restructure item operating segment type company allocate restructuring charge business segment employee employee termination asset write exit termination benefit down cost total dollar million pharmaceutical nutritional healthcare corporateother subtotal reduction reserve change estimate provision restructure item activity company record pretax restructuring charge million restructuring program include termination benefit asset writedown cost implement downsize streamline operation rationalize manufacture facility terminate certain sale force research contract obligation action substantially complete charge million relate employee termination benefit employee result companywide restructuring effort downsize streamline operation impact virtually area include sale force manufacture administrative research personnel additional charge include million termination contract sale force million exit cost primarily relate cost associate closure certain manufacturing operation charge include million writedown fix asset primarily related exit nutritional business eastern europe closure pharmaceutical production facility united states closure research facility france item million relate cost associate product recall restructuring charge partially offset reversal million result change estimate relate separation cost cancellation project previously provide additional cost associate restructuring project include million sale deduction customer charge back relate abandonment nonstrategic pharmaceutical product line include reduction sale million relate inventory writeoff include cost product sell follow table present detail provision restructure item operating segment type company allocate restructuring charge business segment employee asset employee termination write exit termination benefit down cost item total dollar million pharmaceutical nutritional healthcare corporateother subtotal reduction reserve change estimate provision restructure item bristolmyer squibb company note consolidated financial statement continue note restructure item continue rollforward restructuring charge spend liability associate prior current action follow employee termination exit cost liability liability total dollar million balance december charge spend change estimate balance december charge spend change estimate balance december charge spend change estimate balance december liability include accrue expense consolidate balance sheet note acquisition divestiture dupont pharmaceuticals acquisition october company acquire dupont pharmaceutical e du pont de nemour company billion cash result dupont pharmaceutical include consolidated financial statement date acquisition dupont pharmaceutical primarily domestic pharmaceutical imaging product business focus research development acquisition finance proceed issuance billion commercial paper issuance billion mediumterm note internal cash flow follow summary final allocation purchase price estimate fair value asset acquire liability assume dollar million current asset property plant equipment intangible asset acquire inprocess research development goodwill asset total asset acquire current liability restructure liability acquisition liability longterm liability total liability assume purchase price bristolmyer squibb company note consolidated financial statement continue note acquisition divestiture continue total intangible asset million amortize weightedaverage useful life include core develop technology million year weightedaverage useful life respectively patent million year weightedaverage useful life goodwill million assign pharmaceutical segment total million expect deductible tax purpose year period time acquisition billion purchase price allocate acquire inprocess research development charge earning fourth quarter charge associate research project determine identify research project technological feasibility establish alternative future use project terminate remain project clinical stage preclinical currently proceed research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require fda approval connection acquisition company record million restructuring liability result severance relocation workforce elimination duplicate facility contract termination cost recognize company liability assume acquisition date result additional goodwill liability consist million employee termination benefit approximately employee million related closure facility million contract termination million originally record accrue expense reduce million december million december million end reduction balance cash payment million adjustment reverse previously record liability million corresponding reduction goodwill adjustment primarily lower expect separation cost contract termination expense facility exit cost related acquisition reduction balance cash payment million follow unaudited pro forma financial information present result acquisition occur begin restate year end december dollar million share datum net sale net earning earning sharebasic earning sharedilute unaudited pro forma result prepare comparative purpose include certain adjustment additional amortization expense result identifiable intangible asset arise acquisition increase interest expense acquisition debt exclude acquire inprocess research development charge relate dupont pharmaceutical acquisition pro forma net earning earning share amount include billion gain sale clairol pro forma result necessarily indicative result operation actually resulted acquisition effect begin respective period future result company complete sale brand product moisturel duricef result pretax gain million company complete sale pharmaceutical product corzide delestrogen florinef licensing rights corgard united states estrace tablets apothecon commodity business solage viactiv product line result pretax gain million bristolmyer squibb company note consolidated financial statement continue note discontinued operation company complete sale clairol procter gamble cash proceed approximately billion sale result pretax gain billion billion taxis include gain disposal discontinue operation addition company spin zimmer holdings inc zimmer taxfree distribution result common stock dividend million company resolve postclose matter associate previously discontinue business result increase million gain disposal clairol million credit relate reduction tax contingency reserve relate spinoff zimmer million credit retain earning relate adjustment zimmer pension liability affect spinoff zimmer net sale earning discontinue operation follow dollar million net sale earning income taxis income taxis net earning discontinue operation net earning million reflect statement earning primarily reflect reduction tax contingency reserve relate spinoff zimmer consolidate statement cash flow include clairol zimmer business date disposition company use centralized approach cash management financing operation accordingly company allocate debt business cash flow operate investing activity principally invest discontinued operation year end december million billion include approximately billion proceed sale clairol respectively bristolmyer squibb company note consolidated financial statement continue note earning share numerator basic diluted earning share net earning available common stockholder denominator basic earning share weight average number common share outstanding period denominator diluted earning share weight average share outstanding adjusted effect dilutive stock option computation basic earning common share dilute earning common share follow year end december restate restate million share amount earning continue operation discontinue operation net earning net gain disposal net earning basic average common share outstanding earning continue operation discontinue operation net earning net gain disposal net earning dilute average common share outstanding conversion convertible debt bond incremental share outstanding assume exercise dilutive stock option earning continue operation discontinue operation net earning net gain disposal net earning weightedaverage share issuable exercise stock option include diluted earning share calculation dilutive million million million net earning include interest expense add assume conversion convertible debt common share bristolmyers squibb company note consolidated financial statement continue note expense net component expense net year end december restate restate dollar million interest expense interest income foreign exchange transaction loss net net expense net interest expense primarily relate issuance billion debt billion commercial paper conjunction dupont pharmaceutical imclone transaction addition interest expense reduce net interestrate swap gain million million respectively interest income relate primarily cash cash equivalent investment marketable security bristolmyers squibb company note consolidated financial statement continue note income taxis component earning loss continue operation minority interest income taxis year end december restate restate dollar million nonus amount categorize base location tax authority provisionbenefit income taxis attributable continue operation consist year end december restate restate dollar million current nonus defer nonus company provision income taxis different compute apply statutory federal income tax rate earning continue operation minority interest income taxis result follow earning minority interest income taxis restate restate dollar million earning continue operation minority interest income tax statutory rate effect operation ireland puerto rico switzerland state local taxis change estimate contingent tax matter nondeductible reserve foreign effective tax rate continue operation increase primarily decrease effective tax rate benefit operation ireland puerto rico switzerland provision certain nondeductible litigation reserve increase estimate contingent tax matter compare bristolmyer squibb company note consolidated financial statement continue note income taxis continue component current noncurrent defer income tax asset liability december restate dollar million acquire inprocess research development intercompany profit inventory item foreign tax credit carryforward legal settlement restructuring acquisition divestiture reserve defer income alternative minimum tax credit carryforward charitable contribution carryforward state tax net operating loss carryforward foreign net operating loss credit carryforward sale return allowance research experimentation tax credit carryforward postretirement pension benefit depreciation defer foreign currency gainloss net valuation allowance defer tax asset net recognize deferred income tax asset current defer income tax asset noncurrent foreign income taxis payable liability noncurrent valuation allowance million december relate million foreign state net defer tax asset million foreign state net operating loss tax credit carryforward company currently believe likely remain unrealized future income taxis pay year million million million respectively current tax benefit realize exercise stock option charge capital excess par value stock amount million million million respectively company settle federal income tax return internal revenue service irs federal income taxis provide substantially unremitte earning nonus subsidiary management practice intent indefinitely postpone remittance total net unremitted earning nonus subsidiary approximately billion december company establish liability possible assessment tax authority result know tax exposure amount represent reasonable provision taxis ultimately expect pay need adjusted time information know december certain tax contingency liability establish company reasonably estimate possible contingency possible contingency material effect change estimate related contingent tax matter include rate reconciliation year end december company recognize income tax benefit million settlement certain prior year tax matter determination company expect settlement tax litigation bristolmyers squibb company note consolidated financial statement continue note income taxis continue company reorganize structure ownership nonus subsidiary principal purpose reorganization facilitate company ability efficiently deploy financial resource outside united states company believe reorganization transaction generally taxfree inside outside united states possible tax authority particular jurisdiction assert tax liability arise reorganization transaction operation reorganize subsidiary reasonably possible predict tax authority assert tax liability reasonably estimate possible loss range loss respect assert tax liability company vigorously challenge assertion believe prevail assurance result company prevail final non appealable determination possible impact material note receivables major category receivables follow december dollar million account receivabletrade account receivablemiscellaneous allowance bad debt receivables net note inventory major category inventory follow december restate dollar million finish good work process raw packaging material consignment inventory bristolmyers squibb company note consolidated financial statement continue note consignment significant portion company pharmaceutical sale wholesaler april company disclose experience substantial buildup wholesaler inventory pharmaceutical business year primarily buildup primarily sale incentive offer company wholesaler company account certain sale pharmaceutical product cardinal health inc cardinal mckesson corporation mckesson consignment model base relationship incentive offer wholesaler inventory hold wholesaler company determined shipment product cardinal shipment product mckesson meet consignment model criterion set forth note accounting policiesrevenue recognition july july respectively case continue end period accordingly consignment model require apply shipment prior respective period company recognize revenue respect sale cardinal mckesson shipment product company generally view approximately month supply desirable level wholesaler inventory goforward basis level wholesaler inventory representative industry average apply consignment model sale cardinal mckesson company define inventory excess wholesaler ordinary course business inventory level inventory week week supply respectively base level inventory cardinal mckesson require basis negotiation incentive grant march company enter distribution agreement mckesson provision warehousing order fulfillment service company oncology therapeutic network otn specialty distributor anticancer medicine relate product term agreement mckesson purchase oncology product service otns fulfillment need number vendor include company subsequent shipment product mckesson company significant continue involvement transaction include marketing product enduser invoicing customer collect receivables customer behalf mckesson addition otn keep credit risk responsible shipping cost customer company account sale oncology product mckesson consignment model defer recognition revenue product sell mckesson transaction result defer revenue million million december respectively company recognize previously record defer revenue net sale net rebate return adjustment approximately million million respectively bristolmyer squibb company note consolidated financial statement continue note property plant equipment major category property plant equipment follow december restate dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment net capitalize interest include category property plant equipment show company capitalize interest million million year end december respectively note goodwill change carry goodwill year end december follow pharmaceutical nutritional healthcare segment segment segment total dollar million balance december purchase accounting adjustment change exit cost estimate purchase price allocation adjustment balance december restate bristolmyer squibb company note consolidated financial statement continue note intangible asset intangible asset major asset class follow december dollar million patentstrademark license technology accumulate amortization net carrying amortization expense intangible asset majority include cost product sell year end december million million million respectively expect amortization expense year related current balance intangible asset follow year end december dollar million bristolmyer squibb company note consolidated financial statement continue note shortterm borrowing longterm debt include shortterm borrowing amount foreign bank million million current installment longterm debt million million december respectively commercial paper outstanding december commercial paper outstanding december million average interest rate commercial paper issue fully repay december proceed commercial paper issuance general corporate purpose average interest rate international shortterm borrowing current installment longterm debt outstanding december respectively compare respectively december december company revolve credit facility total billion aggregate support domestic commercial paper program facility establish september august respectively syndicate lender extendable anniversary date consent lender revolve credit facility certain financial covenant company compliance december borrowing outstanding revolve credit facility december company unused shortterm line credit foreign bank million million december respectively component longterm debt follow december dollar million note note float rate convertible debenture note note debenture debenture debenture yen note yen note euro interest yen principal term loan industrial revenue bond yen note yen note variable rate industrial revenue bond capitalize lease company issue billion debt follow face value debt description dollar million effective interest rate month libor convertible debt callable strike price month libor note note yen note yen note yen note october company issue billion convertible debenture debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero final maturity september debenture callable par time september issuer holder redeem debenture par september fundamental change ownership bristolmyer squibb company note consolidated financial statement continue note shortterm borrowing longterm debt continue company occur bond initial conversion price conversion rate share adjustable depend average closing price applicable period maximum conversion rate share company enter fixed float interest rate swap billion longterm debt cash payment interest million million million respectively payment period later total year dollar million longterm debt obligation include shortterm borrowing company consolidated balance sheet balance represent outstanding nominal long term debt value december company provide financial guarantee form standby letter credit performance bond majority standby letter credit nuclear regulatory commission massachusetts department public health relate company medical imaging manufacturing operation insurance company support thirdparty liability program performance bond relate sale company product foreign ministry health middle east company believe significant majority guarantee expire funded amount obligation present follow table expiration period total year year dollar million standby letter credit performance bond guarantee total commercial commitment bristolmyers squibb company note consolidated financial statement continue note stockholder equity change common share treasury stock capital excess par value stock restrict stock capital excess common share treasury cost treasury par value restrict issue share stock stock stock dollar million balance december issue pursuant stock plan option conversion prefer stock amortization lapse restrict stock purchase balance december issue pursuant stock plan option conversion prefer stock amortization lapse restrict stock purchase balance december issue pursuant stock plan option conversion prefer stock amortization lapse restrict stock balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock dividend declare common share accumulate balance relate component comprehensive income loss follow accumulate foreign currency available sale defer loss minimum pension comprehensive translation security effective hedge liability adjustment incomeloss dollar million balance december restate comprehensive income loss balance december restate comprehensive income loss balance december restate comprehensive income loss balance december company expect recognize million defer hedging loss net earning month bristolmyer squibb company note consolidated financial statement continue note stockholder equity continue stock compensation plan companys stock incentive plan officer key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price plan provide grant performancebase stock option certain key executive term stock incentive plan authorize share include outstanding share year number share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise share available grant prior year grant year share cancel forfeit expire available future grant plan incorporate company longterm performance award addition stock incentive plan provide grant share common stock key employee subject restriction continuous employment restriction generally expire fiveyear period date grant compensation expense recognize restrict period december respectively restrict share outstanding plan teamshare stock option plan fulltime employee exclude key executive grant option purchase company common stock market price date option grant company authorize share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option share exercise plan december fair value option grant estimate common share common share common share respectively date grant blackschole optionprice model follow assumption dividend yield volatility riskfree interest rate assume forfeiture rate expect life year bristolmyer squibb company note consolidated financial statement continue note stockholder equity continue stock option transaction share common stock weight average exercise price available share option plan plan plan balance december authorize grant grant result zimmer spinoff exercise lapse balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december effective spinoff zimmer august unexercised bristolmyers squibb stock option hold zimmer employee convert zimmer stock option remain unexercised bristolmyer squibb stock option number stock option exercise price adjust preserve intrinsic value stock option ratio exercise price fair value exist prior spinoff follow table summarize information concern company stock compensation plan currently outstanding exercisable option number security remain available future issuance number security weight average exercise equity compensation issue exercise price outstanding plan exclude outstanding option option warrant security reflect warrant right right column plan category b c equity compensation plan approve security holder equity compensation plan approve security holder bristolmyers squibb company note consolidated financial statement continue note stockholder equity continue option outstanding option exercisable range weight average weight average number weight average exercise price number outstanding remain contractual life exercise price exercisable exercise price december share common stock reserve issuance pursuant stock plan option conversion prefer stock option relate discontinued operation include amount material bristolmyer squibb company note consolidated financial statement continue note financial instrument company expose market risk change currency exchange rate interest rate result company utilize foreign exchange option forward contract offset effect exchange rate fluctuation anticipate foreign currency transaction primarily intercompany inventory purchase expect occur year company exposure net foreign currency denominate asset liability approximate million million december respectively primarily europe japan mexico canada foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure relation dollar euro canadian dollar japanese yen notional amount companys foreign exchange derivative contract december million million respectively derivative majority qualify hedge future cash flow effective portion change fair value temporarily record comprehensive income recognize earning hedge item affect earning ineffective portion hedge report earning occur fair value option forward contract liabilitie million million december respectively record accrue liability december fair value foreign exchange contract base yearend currency rate blackschole model case option contract company use derivative instrument interest rate risk management policy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment company enter fix float interest rate swap contract financial institution notional amount swap billion billion december respectively accordance sfas accounting derivative instrument hedging activity company recognize net reduction interest expense million million respectively reflect benefit lower float rate obtain swap compare fix rate underlie debt swap contract underlie debt hedge record fair value result increase current asset longterm debt million million december respectively swap contract generally hold maturity company use derivative financial instrument speculative purpose company reclassify loss million million comprehensive income earning majority classify cost product sell gain million reclassify comprehensive income income expense carry company financial instrument include cash cash equivalent marketable security account receivable account payable approximate fair value december longterm debt note difference fair value carry value material bristolmyer squibb company note consolidated financial statement continue note segment information company organize pharmaceutical company relate healthcare business reportable segmentspharmaceutical otn nutritional healthcare pharmaceutical segment comprise global pharmaceutical international exclude japan consumer medicine business otn segment specialty distributor anticancer medicine relate product otn previously include pharmaceutical segment meet quantitative threshold reportable segment accordingly prior period reclassify conform current year presentation nutritional segment consist mead johnson primarily infant formula business healthcare segment consist convatec medical imaging consumer medicine united states japan business company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital clinic government agency medical profession wholesaler account approximately respectively company total net sale sale wholesaler account respectively company total net sale wholesaler account approximately company total net sale sale concentrate pharmaceutical segment worldwide sale select product product category follows restate restate dollar million pharmaceutical pravachol plavix taxol paraplatin avaproavalide sustiva monopril glucovance glucophage xr zeritzerit er coumadin abilify total revenue videxvidex ec tequin glucophage ir serzone reyataz buspar nutritional infant formulas healthcare ostomy cardiolite wound therapeutic bristolmyers squibb company note consolidated financial statement continue note segment information continue business segment earning minority net sale interest income taxis yearend asset restate restate restate restate restate dollar million pharmaceutical oncology therapeutic network nutritional healthcare total segment corporateother total corporateother principally consist interest income interest expense certain administrative expense allocation business segment certain corporate program corporateother include gain sale businessesproduct line million million respectively accelerate depreciation million termination benefit exit cost million million respectively asset write impairment charge million million respectively upfront payment license agreement million downsize rationalized operation facility million litigation charge net million million million respectively include million asset impairment charge imclone pharmaceutical segment include charge acquire inprocess research development million million respectively additionally pharmaceutical include litigation settlement income million upfront payment licensing agreement million million accelerate depreciation asset manufacturing facility north america expect closed end million charge asset impairment million charge relocation expense million charge retention bonus benefit million deduction customer chargeback relate abandon product line include reduction net sale record corporateother asset include cash cash equivalent marketable security goodwill certain asset capital expenditure depreciation dollar million pharmaceutical oncology therapeutic network nutritional healthcare total segment corporateother total bristolmyer squibb company note consolidated financial statement continue note segment information continue geographic area net sale yearend asset restate restate restate dollar millions united states europe middle east africa western hemisphere pacific total note lease minimum rental commitment noncancelable operating lease primarily real estate effect december year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million bristolmyer squibb company note consolidated financial statement continue note pension postretirement benefit plan company certain subsidiary define benefit pension plan define contribution plan regular fulltime employee principal pension plan bristolmyers squibb retirement income plan fund policy contribute amount provide current service fund past service liability plan benefit base primarily year credit service participant compensation plan asset consist principally equity fix income security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside united states cost company defer benefit postretirement benefit plan include follow component pension benefit benefit restate restate dollar million dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset net amortization deferral net periodic benefit cost curtailment settlement total net periodic benefit cost company elect defer recognition medicare prescription drug improvement modernization act time accumulate postretirement benefit obligation net periodic postretirement benefit cost reflect effect act retiree medical plan specific authoritative guidance account federal subsidy pende fasb guidance issue require change previously report information bristolmyer squibb company note consolidated financial statement continue note pension postretirement benefit plan continue change benefit obligation plan asset december company define benefit postretirement benefit plan pension benefit benefit restate restate dollar million benefit obligation begin year service costbenefit earn year interest cost project benefit obligation plan participant contribution curtailment settlement transfer dupont pharmaceutical actuarial loss plan amendment benefit pay exchange rate loss benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement transfer dupont pharmaceutical transfer benefit pay exchange rate gain fair value plan asset end year fund status unamortized net obligation adoption unrecognize prior service cost unrecognized net actuarial loss net recognize amount recognize balance sheet consist prepay benefit cost accrue benefit cost intangible asset accumulate comprehensive income net recognize plan underfunde accrue benefit obligation exceed accrue benefit liability december additional minimum liability establish increase accrue benefit liability value underfunde accrue benefit obligation total million million december respectively unfunded benefit equalization plan underfunde key international plan plan uk japan canada belgium additional minimum liability offset creation million intangible asset charge comprehensive income include stockholder equity million million december respectively accumulate benefit obligation define benefit pension plan million million december respectively bristolmyer squibb company note consolidated financial statement continue note pension postretirement benefit plan continue information pension plan accumulate benefit obligation excess plan asset december restate dollar millions project benefit obligation accumulate benefit obligation fair value plan asset attributable primarily unfunded benefit equalization plan plan international market unfunde benefit equalization plan provide pension benefit employee compensation irs limit fund taxadvantage manner additional information pertaining company pension postretirement plan pension benefit benefit restate restate dollar million increase minimum liability include comprehensive income weightedaverage assumption determine benefit obligation december pension benefit benefit restate restate discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december pension benefit benefit restate restate discount rate expect longterm return plan asset rate compensation increase company expect longterm rate return pension plan asset target asset allocation public equity international private equity fix income approximate apply expect return public equity private equity fix income target allocation actual historical return relevant annualize return period end december year year year pension plan asset represent total company pension plan asset december disclose total company expect return asset pension plan impact international pension plan typically employ aggressive asset allocation expect return disclose benefit relevant asset invest manner pension plan asset international plan asset bristolmyers squibb company note consolidated financial statement continue note pension postretirement benefit plan continue assume health care cost trend rate december health care cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume health care cost trend rate effect amount report health care plan onepercentagepoint change assume health care cost trend rate follow effect percentage percentage point increase point decrease dollar million effect total service interest cost effect postretirement benefit obligation company asset allocation pension postretirement benefit december pension benefit benefit restate restate public equity security debt security include cash private equity total company investment strategy emphasize equity order achieve high expect return long run low expense low require cash contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow ie cash contribution benefit payment rebalance target necessary investment diversify major asset category equity passively manage investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative bristolmyer squibb company common stock represent plan asset december asset postretirement benefit commingle pension plan asset investment strategy identical describe pension plan contribution result improve investment return significant contribution recent year current plan cash contribution pension plan significant tax deductible contribution likely allow irs rule minimum contribution require contribution pension plan company taxdeductible contribution h account retiree medical benefit equal portion pension normal cost contribution international pension plan expect million range bristolmyer squibb company note consolidated financial statement continue note pension postretirement benefit plan continue estimate future benefit payment follow benefit payment reflect expect future service appropriate expect pay pension benefit benefit dollar million year saving plan principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency lawsuit claim proceeding investigation pende company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate matter involve antitrust security patent infringement employee retirement income security act amend erisa pricing sale marketing practice environmental health safety matter product liability insurance coverage significant matter describe fourth quarter company establish reserve liabilitie million comprise million relation wholesaler inventory issue certain accounting matter discuss security matter million relation pharmaceutical pricing sale marketing practice discuss pricing sale promotional practice litigation investigation possible time reasonably assess final outcome matters accordance gaap company determine amount represent minimum expect probable loss respect group matter eventual loss relate matter exceed reserve impact group matter material company believe topend range loss estimate exception accrual taxol buspar environmental product liability proceeding company establish reserve matter describe assurance increase scope matter future lawsuit claim proceeding investigation material management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity plavix litigation company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute u district court southern district new york entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v dr reddys laboratories ltd dr reddys laboratories inc cv rws similar proceeding involve plavix institute outside united states suit file march respectively base patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel market plavix patent disclose claim thing use clopidogrel prevent secondary ischemic event plaintiff later withdraw patent lawsuit plaintiff infringement position base defendant file abbreviate new drug application anda fda seek approval sell generic clopidogrel prior expiration composition matter patent defendant respond allege patent invalid andor unenforceable case consolidate discovery fact discovery close october teva pharmaceuticals usa teva generic drug manufacturer file anda fda claim patent relate plavix invalid infringe teva patent involve pende patent infringement litigation involve plavix teva filing challenge patent issue plavix litigation expect impact litigation appear teva intend commercialize generic form plavix prior expiration termination patent issue litigation assurance continue case net sale plavix approximately billion expect grow substantially year company anticipate revenue growth important factor offset expect decrease sale company product recently experience exclusivity loss period currently company expect plavix market exclusivity united states composition matter patent plavix find infringe invalid andor unenforceable district court level fda approve defendant andas sell generic clopidogrel generic competition plavix begin company exhaust appeal generic competition likely result substantial decrease sale plavix united states plaintiff intend vigorously pursue enforcement patent right plavix possible time reasonably assess outcome lawsuit company prevail lawsuit time potential generic competition plavix generic competition occur company believe unlikely occur year possible reasonably estimate impact lawsuit company loss market exclusivity plavix subsequent development generic competition material company sale plavix result operation cash flow material financial condition liquidity bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue vanlev litigation april june company chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd name defendant number class action lawsuit allege violation federal security law regulation action consolidate action district court district new jersey plaintiff claim defendant disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability product vanlev period november april plaintiff submit amend complaint add allegation company present chairman board chief executive officer peter r dolan chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability vanlev period april march number relate class action make essentially allegation file district court southern district new york action transfer district court district new jersey company file motion partial judgment favor base pleading plaintiff oppose motion seek amend complaint include attempt expand propose class period court rule company motion dismiss plaintiff motion leave amend discovery ongoing plaintiff purport seek compensatory damage cost expense behalf shareholder possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determination litigation impact material security matter period march company number current officer name defendant number security class action suit suit variously allege violation federal security law regulation connection different matter vanlev discuss sale incentive wholesaler inventory level imclone imclone product erbitux discuss allegation concern vanlev transfer district court district new jersey consolidated action pende remain action consolidate pende district court southern district new york plaintiff file consolidated class action complaint april company certain current officer allege class period october march consolidated class action complaint allege violation federal security law connection thing company investment relationship imclone imclone product erbitux certain accounting issue address restatement include issue relate wholesaler inventory sale incentive establishment reserve account certain asset sale plaintiff seek compensatory damage cost expense august company move dismiss consolidated class action complaint plaintiff oppose company motion dismiss company reply motion remain pende court discovery matter stay pursuant private security litigation reform act addition action file early october new york state court make similar factual allegation assert variety claim include common law fraud negligent misrepresentation discovery take matter january company move dismiss complaint begin october number company current officer director name defendant shareholder derivative suit pende district court southern district new york number company current officer director name defendant shareholder derivative suit file period march district court district new jersey july district court district new jersey order shareholder derivative lawsuit file court transfer district court southern district new york subsequently district court southern district new york order federal shareholder derivative suit consolidated plaintiff file consolidated amend verify shareholder complaint certain member board director current officer pricewaterhousecooper pwc company independent auditor company nominal defendant consolidate amend complaint allege thing violation federal security law breach fiduciary duty certain individual defendant connection company conduct concern thing safety efficacy commercial viability vanlev discuss company sale incentive certain wholesaler inventory level wholesaler company investment bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue relation imclone imclone product erbitux allege anticompetitive behavior connection buspar taxol lawsuit allege malpractice negligent misrepresentation negligence pwc plaintiff seek restitution rescission certain officer director compensation allege improper insider trading proceed injunctive relief fee cost expense contribution certain officer allege liability consolidated security class action pende district court southern district new york discuss contribution indemnification pwc discovery take matter december company move dismiss consolidate amend complaint similar action pende new york state court plaintiff seek equitable relief damage cost attorney fee sec attorney office grand jury district new jersey investigate activity company certain current member company management connection wholesaler inventory issue reference certain accounting issue company cooperate investigation possible time reasonably assess final outcome litigation investigation reasonably estimate possible loss range loss respect litigation investigation company produce document actively cooperate investigation investigation result assertion civil andor criminal claim company andor current member company management company prevail final nonappealable determination litigation investigation impact material erisa litigation december quarter company name defendant class action bring erisa district court southern district new york district new jersey action consolidated southern district new york caption bristolmyers squibb co erisa litigation cv amend consolidated complaint allege class period january march serve august amend consolidated complaint bring behalf name plaintiff putative class consist participant bristolmyers squibb company saving investment program saving planand beneficiary benefit saving plan hold andor acquire company stock time class period exclude defendant heir predecessor successor assign name defendant company bristolmyer squibb company saving plan committee committee thirteen individual presently serve committee serve committee recent past charle heimbold jr peter r dolan past present chief executive officer respectively company amend consolidated complaint generally allege defendant breach fiduciary duty erisa class period thing continue offer company stock fund company stock investment alternative saving plan continue invest company matching contribution company stock fund company stock fail disclose investment company stock allegedly imprudent saving plan purchase company stock january allege transaction prohibit erisa finally defendant heimbold dolan allege breach fiduciary duty erisa fail monitor action committee erisa claim predicate factual allegation similar raise security matter concern thing safety efficacy commercial viability vanlev company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone imclone product erbitux allege anticompetitive behavior connection buspar taxol significant discovery october company defendant move dismiss amend consolidated complaint plaintiff oppose motion dismiss defendant reply possible time reasonably predict final outcome reasonably estimate possible loss range loss respect consolidated litigation company prevail final nonappealable determination matter impact material pricing sale promotional practice litigation investigation company number pharmaceutical manufacturer defendant private class action action bring nevada montana attorney general county suffolk westchester rockland new york pende federal state court relate price certain company product federal case consolidate pretrial purpose caption pharmaceutical industry average wholesale price litigation mdl district court district massachusetts awp multidistrict litigation bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue june court awp multidistrict litigation grant private plaintiff motion leave file amend master consolidated complaint amend master complaint amend master complaint contain set allegation company allege company pharmaceutical manufacturer report price certain drug product list drug company case effect falsely overstate average wholesale price awp publish industry compendia turn improperly inflate reimbursement pay medical provider prescribe administer product second allege company certain defendant pharmaceutical manufacturer conspire program call rx card program fix awps certain drug available consumer program amend master complaint assert claim federal rico antitrust statute state consumer protection fair trade statute amend master complaint bring behalf main propose class divide subclass person entity forward directly pay portion price list drug price calculate reference awp b contract pharmacy benefit manager provide drug list amend consolidated complaint person entity forward pay reimburse portion purchase price drug cover rx card program base awp company defendant move dismiss amend master complaint ground fail state claim applicable statute motion deny february court dismiss plaintiff claim failure plead cognizable rico enterprise accordingly company defendant require answer amend master complaint addition company engage continue engage discovery private class action awp multidistrict litigation nevada montana attorney general complaint assert claim similar amend master complaint state law assert claim respective state allege violation state medicaid fraud statute nevada montana attorney general case originally commence respective state court later remove awp multidistrict litigation attorney general move case remand state court ground federal jurisdiction june court awp multidistrict litigation rule nevada action company name remand state court ground defendant join original removal petition case proceed nevada state court court retain jurisdiction montana case defendant move dismiss montana second nevada case company name oral argument hear motion december ruling issue finally company defendant relate state court proceeding commence new york new jersey california arizona tennessee proceedings attorney general pennsylvania federal court proceeding commence county suffolk westchester rockland new york collectively new york county awp case proceeding transfer awp multidistrict litigation pretrial purpose plaintiff california arizona new jersey action seek remand case state court california remand motion deny arizona remand motion grant remand motion remain pende new york county awp case allege rico claim similar amend master consolidated complaint awp multidistrict litigation claim behalf county contributor new york states medicaid obligation defendant firstfile suffolk county case move dismiss amend complaint action oral argument hear motion december ruling issue respect case remand arizona state court defendant file motion dismiss stay hear motion currently schedule june merit discovery stay case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination litigation investigation impact material company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing sale marketing practice good price report drug cover medicare andor medicaid request record come attorney office district massachusetts office inspector general department health human service conjunction civil division department justice office inspector general office personnel management conjunction attorney office eastern district pennsylvania state addition request information come house committee energy commerce connection investigation committee bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue currently conduct medicaid good price issue finally company receive civil investigative demand attorney general state missouri relate direct consumer advertising pravachol period company receive notice putative class action lawsuit involve issue file february circuit court jackson county missouri kansas city caption richard summers v bristolmyers squibb company company serve complaint july company announce recently initiate internal review certain sale marketing practice review focus practice comply applicable antikickback law include analysis practice respect compliance good price reporting rebate requirement medicaid program certain governmental programs reference medicaid rebate program applicable fda requirement company meet representative attorney office district massachusetts discuss review company receive subpoena attorney office district massachusetts companys internal review expect continue resolution pende governmental investigation relate matter company produce document actively cooperate investigation result assertion civil andor criminal claim company unable assess outcome reasonably estimate possible loss range loss respect investigation include imposition fine penalty administrative remedy andor liability additional rebate amount company prevail final non appealable determination litigation investigation impact material ctlaig litigation august repligen corporation repligen university michigan institute lawsuit company district court eastern district michigan suit allege dr craig thompson professor university michigan involve collaboration certain company scientist thompson activity collaboration rightful inventor patent company later obtain cover soluble form ctla relate method use conduct trial september district court rule repligen university michigan fail prove thompson inventive contribution patent suit entitle add sole joint inventor company patent repligen university michigan appeal district court decision court appeal federal circuit erbitux litigation october complaint file yeda research development company ltd yeda imclone system aventis pharmaceuticals inc district court southern district new york action allege seek individual associate yeda name coinventor patent cover therapeutic combination egfr monoclonal antibody antineoplastic agent chemotherapeutic agent use treatment cancer yeda action successful yeda position practice license practice invention result product competition erbitux occur company party action unable predict outcome stage proceeding product liability litigation company party product liability lawsuit involve allegation injury cause company pharmaceutical overthecounter medication majority lawsuit involve certain overthecounter medication contain phenylpropanolamine ppa company serzone stadol n prescription drug addition lawsuit company face unfiled claim involve product ppa yale university publish result hemorrhagic stroke project conclude evidence suggestion ppa increase risk hemorrhagic stroke limited population november fda issue public health advisory request manufacturer ppacontaining product voluntarily cease manufacturing marketing time ppacontaining product manufacture sell company comtrex liquid gel formulation naldecon november company manufacturer ppa contain product discontinue manufacture marketing ppa contain product allow customer return unused product possession january company serve ppa lawsuit company currently defendant approximately personal injury lawsuit file behalf approximately plaintiff federal state court bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue united states majority lawsuit involve multiple defendant claim plaintiff allege ppa cause hemorrhagic ischemic stroke defendant aware risk fail warn consumer fail remove ppa product plaintiff seek compensatory punitive damage federal case transfer district court western district washington phenylpropanolamine ppa product liability litigation mdl district court deny motion class certification class action lawsuit pende company litigation june district court issue rule effectively limit plaintiff claim hemorrhagic ischemic stroke ruling favorable defendant include inadmissibility expert testimony case allege injury occur day ingestion ppa contain product case involve psychosis seizure cardiac injury company expect dismiss additional case product plaintiff plaintiff allege injury occur day ingestion ppa contain product plaintiff suffer cardiac injury psychose serzone serzone nefazodone hydrochloride antidepressant launch company canada march united states december company add black box warn serzone label warn potential risk severe hepatic event include possible liver failure need transplantation risk death month black box warning add package insert serzone number lawsuit include class action file company plaintiff allege company know know hepatic risk pose serzone failed adequately warn physician user risk seek compensatory punitive damage medical monitoring refund cost purchase serzone present company lawsuit behalf plaintiff pende federal state court united states case pende new york state court consolidated pretrial discovery addition approximately allege unfiled claim injury associate serzone august federal case transfer district court southern district west virginia serzone product liability litigation mdl discovery early stage appear case involve liver failure june district court dismiss class claim class action complaint number class action complaint file company seek certification personal injury class remain class action complaint seek certification personal injury class january court issue order set hearing class certification october addition case file united states national class action file canada stadol ns stadol n approve fda unschedule opioid analgesic nasal spray february company ask fda schedule stadol n schedule iv low potential abuse drug postmarketing report suggestive inappropriate use product october schedule iv drug company receive number lawsuit involve stadol late number file suit increase newly pass tort reform legislation effective january plaintiff new suit previously assert claim company allege injury company currently party case pende behalf total approximately plaintiff federal state court united states plaintiff claim company commit fraud fda wrongfully promote stadol ns nonaddictive plaintiff allege company fail adequately warn addiction dependency risk associate use stadol ns addition lawsuit approximately allege unfiled claim approximately active majority case claim pende mississippi addition case file united states class action individual case file canada breast implant litigation company subsidiary medical engineering corporation mec certain company remain defendant number claim lawsuit allege damage personal injury type result polyurethanecovered breast implant smoothwalle breast implant manufacture mec relate company vast majority claim company direct lawsuit resolve settlement trial likewise claim potential claim company register nationwide class action settlement approve federal district court birmingham alabama revise settlement resolve revise settlement company establish accrual respect breast implant product liability litigation company believe possible loss addition amount accrue material company intends vigorously defend product liability lawsuit believe majority case claim merit possible time reasonably assess final outcome company pende product liability lawsuit unfiled claim certainty management opinion ultimate disposition matter material adverse effect company financial position company believe adequate selfinsurance reserve commercially available excess insurance cover potential loss relate product liability case claim bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue platinol litigation february class action complaint file north shore hematologyoncology associate pc company district court district columbia putative class action bring behalf direct purchaser platinol allege company violate federal antitrust law maintain monopoly market allegation focus company action concern patent patent include procurement patent submission information relate patent list orange book initiation previous lawsuit potential generic manufacturer base patent plaintiff seek declaratory judgment damage include treble damage company market platinol exclusive patent license research corporation technology rct federal trade commission ftc open investigation relate platinol matter settle entry consent decree effect april possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determination litigation impact material taxol litigation number putative class action bring company allege antitrust consumer protection similar claim concern company action obtain enforce patent right relate taxol number state attorney general bring similar claim certain insurer assert similar claim filing suit matter settle require court approval give final approval supervise court total settlement million million accrue remaining million accrue ftc open investigation relate taxol matter settle entry consent decree effect april additional case base allegation bring small generic drug manufacturer company move dismiss case court grant motion july plaintiff seek reconsideration decision unsuccessful plaintiff file notice appeal court appeal seventh circuit possible time reasonably assess final outcome suit reasonably estimate possible loss range loss dismissal reverse dismissal reverse company prevail final nonappealable determination action impact material buspar litigation number putative class action bring company allege antitrust consumer protection similar claim concern company action obtain enforce patent right relate buspar number state attorney general bring similar claim certain insurer generic drug manufacturer chain drug store assert similar claim matter settle require court approval give final approval supervise court total settlement million million accrue million accrue remaining million accrue ftc open investigation relate buspar matter settle entry consent decree effect april environmental proceeding follow discussion describe environmental proceeding governmental authority involve potential monetary sanction threshold prescribe specific sec rule civil action environmental claim result significant liability update ongoing matter resolution matter disclose recent public filing summary environmental remediation cost bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue preliminary result internal audit perform company facility hopewell nj indicate operation site wastewater treatment plant relate discharge compliance new jersey water pollution control act implement regulation term company discharge permit company report finding new jersey department environmental protection njdep february currently engage settlement discussion state result audit suggest adverse impact public health company take continue corrective action address identify deficiency prevent future occurrence january njdep send company approximately company information request letter relate site north brunswick township nj waste material er squibb son squibb wholly own subsidiary bms disposed fill material contain industrial waste heavy metal excess residential standard discover fall expansion project north brunswick township high school school board township current owner site prepare submit workplan njdep ask company contribute cost remediation company discussion njdep site owner potentially responsible party site investigation ongoing claim assert company september njdep issue administrative enforcement directive notice new jersey spill compensation control act require company approximately company perform assessment natural resource damage implement unspecified interim remedial measure restore condition low passaic river directive allege company liable historically send bulk waste inland chemical company facility newark new jersey release hazardous substance facility migrate newark bay continue adverse impact low passaic river watershe subsequently environmental protection agency usepa issue notice letter comprehensive environmental response compensation liability act cercla numerous partiesbut include bmsseeke cooperation study condition substantially stretch passaic river subject njdep directive usepa estimate study cost million study lead cleanup action direct usepa army corps engineer extent liability directive usepas notice letter determined company believe bms caused contribute contamination low passaic river watershe company inform njdep willing discuss allegation company njdep directive state responsible party cooperate njdep perform damage assessment restoration civil action recover remedial cost treble damage administrative cost penalty october michigan department environmental quality mdeq send company letter violation lov allege unspecified period time emission certain digestion tank mead johnsons zeeland michigan facility exceed applicable limit facilitys renewable operating air permit lov require company corrective action submit compliance program report mdeq demand fine penalty enforcement action result penalty injunctive relief company contest allegations lov july njdep advise squibb believe company violate clean air act fail comply prevention significant deterioration requirement connection replacement gas turbine company cogeneration facility new brunswick new jersey facility december company settle matter njdep sign administrative consent order require company submit permit application create facilitywide emission cap pay administrative fine approximately environmental quality board puerto rico issue notice bristolmyer squibb allege violation federal resource recovery conservation act relate recordkeeping storage requirement hazardous waste company facility humacao base prior dealing eqb technical nature allege violation company believe penalty impose significant company defendant class action suit file superior court puerto rico february resident allege air emission government own operate wastewater treatment facility barceloneta cause respiratory ailment violate local air rule company believe wastewater discharge treatment facility material compliance term company permit company believe litigation resolve immaterial suit initial stage event adverse judgment company ultimate financial liability significantly great anticipate bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue company responsible state federal foreign law include cercla certain cost investigate remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party company estimate cost base information obtain usepa relevant agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party prp company accrue liability probable reasonably estimable company estimate share total future cost site approximately million represent sum good estimate simple estimate reasonably estimate minimum cost take account potential recovery party currently expect company pay million exclude legal fee year investigation remediation matter include liability cercla onsite remediation possible predict certainty outcome environmental proceeding ultimate cost remediation company believe reasonably possible expenditure company incur excess exist reserve material adverse effect business financial position result operation indemnification officer director companys corporate bylaw require extent permit law company shall indemnify officer director judgments fine penalty amount pay settlement include legal fee appeal incur connection civil criminal action proceeding relate service company subsidiary bylaw provide limit indemnification indemnification permit case willful misconduct know violation criminal law improper personal benefit permit law state delaware company year purchase director officer insurance coverage cover claim director officer amount type coverage varied period period dictate market condition excess policy provide additional coverage litigation matter regulatory action describe involve certain company current director officer cover aforementioned indemnity applicable certain prior period insurance policy certain indemnification payment cover company director officer insurance coverage company predict certainty extent company recover insurer indemnification payment connection litigation matter regulatory action describe july company insurer federal insurance company file lawsuit new york supreme court company current officer member board director seek rescission alternative declaration allow federal avoid payment certain director officer insurance policy certain fiduciary liability insurance policy respect potential liability arise connection matter describe vanlev litigation security matter erisa litigation section discovery take matter october company insurer sr international business insurance co ltd sri inform company intend try avoid certain insurance policy issue company ground allege material misrepresentation nondisclosure initiate arbitration proceeding london england sri indicate intend rely allegation similar describe security matter section support avoidance action possible time reasonably assess final outcome matter reasonably estimate possible loss range loss respect matter company prevail final nonappealable determination matter impact material bristolmyer squibb company note consolidated financial statement continue note subsequent event december company confirm mead johnson wholly own subsidiary company reach agreement novartis ag novartis sell novartis adult nutritional business term agreement novartis acquire brand trademark patent intellectual property right mead johnson global adult medical nutrition business million include million contingent product conversion million upfront payment supply agreement transaction close february pretax gain approximately million expect record quarter adult nutritional product record sale million company announce january agree acquire acordis specialty fibre acordis privately hold company base united kingdom license patent right supply material convatec wound therapeutic line transaction subject regulatory approval receive transaction complete company expect record inprocess research development charge million million fda approve bla erbitux anticancer agent company develop partnership imclone february erbitux injection use combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer refractory irinotecan base chemotherapy use single agent treatment patient egfrexpresse metastatic colorectal cancer intolerant irinotecan base chemotherapy accordance agreement company pay imclone march million milestone payment approval erbitux fda bristolmyers squibb company note consolidated financial statement continue note select quarterly financial datum unaudite select quarterly financial datum set forth note revise reflect restatement discussion restatement note restatement previously issue financial statement year end december quarter second quarter quarter previously previously previously dollar million share datum report restate report restate report restate net sale gross margin net earning earning common share basic dilute dividend declare common share cash cash equivalent marketable security dollar million share datum net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security bristolmyers squibb company note consolidated financial statement continue note select quarterly financial datum unaudite continue fourth quarter year dollar million share datum report report net sale gross margin net earning earning common share basic dilute dividend declare common share cash cash equivalent marketable security fourth quarter year previously previously dollar million share datum report restate report restate net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security bristolmyers squibb company note consolidated financial statement continue note select quarterly financial datum unaudite continued note earning share quarter add amount year period compute discrete basis include litigation settlement charge million million second fourth quarter respectively second quarter include litigation settlement income million million million respectively second fourth quarter include provision restructure item million million million million respectively second fourth quarter include reversal prior period restructure item million million million respectively fourth quarter include upfront payment license agreement million million respectively includes gain sale product line million quarter fourth quarter include writeoff acquire inprocess research development million million million respectively second fourth quarter include provision restructure item million million respectively quarter include reversal prior period restructure item million million respectively litigation settlement charge million million include quarter respectively quarter include million asset impairment charge imclone principal correction interim period restatement discuss note restatement previously issue financial statement year end december intercompany foreign exchange gain loss quarter wic rebate accrual second quarter minority interest tax adjustment quarter intercompany foreign exchange gain loss income taxis vacation accrual quarter common equivalent share exclude computation dilute earning share effect antidilutive follow million second fourth quarter quarter quarter quarter year quarter discontinue operation result include purchase price adjustment relate clairol transaction million million net tax quarter discontinue operation result include litigation provision million million net tax gain adjustment relate clairol transaction million million net tax fourth quarter discontinue operation result include million reduction provision income taxis reduction tax contingency reserve relate zimmer spinoff principal correction interim period restatement discuss note restatement previously issue financial statement year end december intercompany foreign exchange gain loss quarter good transit adjustment provision income taxis fourth quarter report independent auditor board director stockholder bristolmyers squibb company opinion consolidated financial statement list index appear item present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america addition opinion financial statement schedule list index appear item present fairly material respect information set forth read conjunction relate consolidated financial statement financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion describe note restatement previously issue financial statement year end december company restate previously issue financial statement describe note accounting policy company change method accounting business combination goodwill arising transaction consummate subsequent june change method accounting goodwill arising transaction consummate prior july impairment longlive asset pricewaterhousecooper llp pricewaterhousecooper llp philadelphia pennsylvania march item change disagreement accountant account financial disclosure item control procedure company restate consolidated balance sheet december consolidate statement earning cash flow comprehensive income retain earning year end december financial statement second quarter include comparable interim period restatement discussion individual restatement adjustment item financial statementsnote restatement previously issue financial statement year end december december company carry evaluation supervision participation chief executive officer chief financial officer pursuant rule promulgate securities exchange act amend effectiveness design operation disclosure control procedure make evaluation company consider matter relate restatement include action take company past year identify enhance effectiveness disclosure control procedure internal control financial reporting complete restatement company continue identify implement action improve effectiveness disclosure control procedure internal control financial reporting connection effort company substantially strengthen organization personnel senior financial control function ii adopt rigorous policy procedure respect balance sheet review process iii focus internal audit function financial reporting control iv engage consultant assist evaluation documentation certain financial reporting disclosure process company v engage consultant assist comprehensive detailed review certain company tax reporting accounting addition request company audit committee company independent auditor perform extensive procedure respect company interim financial information base auditor assessment company risk profile expand scope field work perform certain area connection audit company action contribute significantly company identify additional error relate prior period reflect restatement march company restate financial statement year end december include correspond interim period second quarter include comparable prior interim period restatement connection audits restatement company consolidate financial statement year end december company independent auditor pricewaterhousecooper llp pwc identify communicate company audit committee material weakness define standard establish american institute certify public accountant relate company account public financial report significant matter initial recording management review oversight certain accounting matter addition time pwc identify communicate company audit committee reportable condition define standard establish american institute certify public accountant relate company internal control financial reporting income taxis connection audit company consolidate financial statement year end december pwc advise company audit committee reportable condition income tax accounting area remain company dedicate substantial resource improve control account financial disclosure reporting auditor identify material weakness connection audit financial statement addition company devote substantial resource remedy reportable condition relation taxis company effort strengthen financial internal control continue company expect complete remediation reportable condition end base evaluation company chief executive officer chief financial officer conclude evaluation date disclosure control procedure reasonably design ensure information require disclose company report file submit exchange act record process summarize report time period specify rule forms securities exchange commission describe evaluation date company management internal control significant change internal control factor significantly affect internal control iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item b information require item respect executive officer registrant include ia reliance general instruction g instruction item b regulation sk item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item iv item